Issue
Date Log
Copyright (c) 2026 Amal Mohammed Abdullah Ibn Mandeel, Aishah Hassan Ali Magrashi, Mashael Hussain Albalushei, Amal Saif Alsubaei, Waad Saad Aldossari, Aisha Marie Alsayed, Salmah Mansour Alazmi, Athyaha Hanaif Okashan Alruwaili, Wushaylah Qasem Ali Ahmadi, Fatima Qasim Ali Ahmadi, Hanan Abdulrahman Abdulah Ali, Shafega Ali Shajri

This work is licensed under a Creative Commons Attribution 4.0 International License.
Candidemia in Immunocompromised Patients: Dental Diagnosis, Treatment, and Nursing Care-An Updated Review
Corresponding Author(s) : Amal Mohammed Abdullah Ibn Mandeel
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Candidemia is a major healthcare-associated bloodstream infection associated with substantial morbidity and mortality, particularly among critically ill and immunocompromised patients. Its management remains challenging because of diagnostic delays, increasing antifungal resistance, and differences in the epidemiology of Candida species across geographical regions.
Aim: This review examines the epidemiology, antifungal susceptibility, diagnostic approaches, and current therapeutic strategies for candidemia, with emphasis on emerging resistance patterns and clinical management challenges.
Methods: Relevant literature was reviewed to summarize the distribution of Candida species, regional antifungal resistance profiles, and advances in diagnostic methods. The review also evaluates conventional blood cultures, molecular techniques, next-generation sequencing, T2 Candida, MALDI-TOF, non-culture-based biomarkers, and biosensors. Therapeutic approaches, including antifungal prophylaxis, empirical and targeted treatment, vascular catheter removal, ophthalmological assessment, therapeutic monitoring, and emerging antifungal agents, were also examined.
Results: Non-albicans Candida species are increasingly contributing to candidemia, with substantial geographical variation in antifungal susceptibility. Although blood cultures remain the diagnostic reference standard, their limited sensitivity and delayed results support the use of rapid molecular and biomarker-based techniques. Echinocandins remain the preferred initial treatment for many non-neutropenic patients with candidemia. However, treatment outcomes are influenced by species identification, antifungal susceptibility, infection site, pharmacokinetic and pharmacodynamic factors, and timely source control. New agents, including rezafungin and fosmanogepix, offer potential therapeutic alternatives.
Conclusion: Improved outcomes require early diagnosis, appropriate antifungal selection, source control, and individualized management guided by microbiological findings and patient characteristics.
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Mora Carpio, A.L.; Climaco, A. Candidemia. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025.
- 2. Lass-Flörl, C.; Kanj, S.S.; Govender, N.P.; Thompson, G.R.; Ostrosky-Zeichner, L.; Govrins, M.A. Invasive candidiasis. Nat. Rev. Dis. Prim. 2024, 10, 20.
- 3. McCarty, T.P.; White, C.M.; Pappas, P.G. Candidemia and Invasive Candidiasis. Infect. Dis. Clin. N. Am. 2021, 35, 389–413.
- 4. Uraguchi, K.; Makino, T.; Kariya, S.; Noda, Y.; Marunaka, H.; Doi, A.; Kozakura, K.; Takao, S.; Ando, M. Candidemia in patients with head and neck cancer: Mortality and a novel risk factor. Support. Care Cancer 2022, 30, 5921–5930.
- 5. Atiencia-Carrera, M.B.; Cabezas-Mera, F.S.; Tejera, E.; Machado, A. Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis. PLoS ONE 2022, 17, e0263522.
- 6. Harchand, R.; Spruijtenburg, B.; Meijer, E.F.J.; de Groot, T.; Rudramurthy, S.M.; Meis, J.F. Candida vulturna, the Next Fungal Menace? A Narrative Review. Mycoses 2025, 68, e70070.
- 7. Pérez-Camacho, P.M.; Vargas-Moran, C.; Torres-Canchala, L.; Ariza-Insignares, C.; Sandoval-Calle, L.M.; Gómez-Hernández, I.E.; Solís-Núñez, P.; Cedeño-Castaño, J.V.; Aguilar-González, A.M.; Patiño-Niño, J.A. Epidemiological characteristics of pediatric patients with invasive candidiasis in an intensive care unit in southwestern Colombia. Biomedica 2025, 45, 151–164.
- 8. Cook, A.; Ferreras-Antolin, L.; Adhisivam, B.; Ballot, D.; Berkley, J.A.; Bernaschi, P.; Carvalheriro, C.G.; Chaikittisuk, N.; Chen, Y.; Chibabhai, V. Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study. Med. Mycol. 2023, 61, myad010.
- 9. Brescini, L.; Mazzanti, S.; Orsetti, E.; Morroni, G.; Masucci, A.; Pocognoli, A.; Barchiesi, F. Species distribution and antifungal susceptibilities of bloodstream Candida isolates: A nine-years single center survey. J. Chemother. 2020, 32, 244–250.
- 10. Posteraro, B.; De Carolis, E.; Criscuolo, M.; Ballanti, S.; De Angelis, G.; Del Principe, M.I.; Delia, M.; Fracchiolla, N.; Marchesi, F.; Nadali, G. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses 2020, 63, 900–910.
- 11. Egger, M.; Salmanton-García, J.; Barac, A.; Gangneux, J.P.; Guegan, H.; Arsic-Arsenijevic, V.; Matos, T.; Tomazin, R.; Klimko, N.; Bassetti, M.; et al. ECMM Candida III Study Group Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III multinational European observational cohort study. Mycopathologia 2023, 188, 983–994.
- 12. Liu, T.; Sun, S.; Zhu, X.; Wu, H.; Sun, Z.; Peng, S. Epidemiology, clinical characteristics, and outcome in candidemia: A retrospective five-year analysis from two tertiary general hospitals. BMC Infect. Dis. 2025, 25, 512.
- 13. Zhang, W.; Song, X.; Wu, H.; Zheng, R. Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients. BMC Infect. Dis. 2020, 20, 506.
- 14. Kajihara, T.; Yahara, K.; Nagi, M.; Kitamura, N.; Hirabayashi, A.; Hosaka, Y.; Abe, M.; Miyazaki, Y.; Sugai, M. Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010–2019: A retrospective observational study based on national surveillance data. Med. Mycol. 2022, 60, myac071.
- 15. Doğan, Ö.; Yeşilkaya, A.; Menekşe, Ş.; Güler, Ö.; Karakoç, Ç.; Çınar, G.; Kapmaz, M.; Aydin, M.; Keske, S.; Sahin, S.; et al. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group. Int. J. Antimicrob. Agents 2020, 56, 105992.
- 16. Arastehfar, A.; Yazdanpanah, S.; Bakhtiari, M.; Fang, W.; Pan, W.; Mahmoudi, S.; Pakshir, K.; Daneshina, F.; Boekhout, T.; Ilkit, M.; et al. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018). Med. Mycol. 2021, 59, 422–430.
- 17. Szekely, J.; Rakchang, W.; Rattanaphan, P.; Kositpantawong, N. Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak. Epidemiol. Infect. 2023, 151, e146.
- 18. Pappas, P.G.; Vazquez, J.A.; Oren, I.; Rahav, G.; Aoun, M.; Bulpa, P.; Ben-Ami, R.; Ferrer, R.; Mccarty, T.; Thompson, G.R.; et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: Results from a Phase 2 trial. J. Antimicrob. Chemother. 2023, 78, 2471–2480.
- 19. Shuping, L.; Mpembe, R.; Mhlanga, M.; Naicker, S.D.; Maphanga, T.G.; Tsotetsi, E.; Wadula, J.; Velaphi, S.; Nakwa, F.; Chibabhai, V. Epidemiology of culture-confirmed candidemia among hospitalized children in South Africa, 2012–2017. Pediatr. Infect. Dis. J. 2021, 40, 730–737.
- 20. Huang, Y.S.; Wang, F.D.; Chen, Y.C.; Huang, Y.T.; Hsieh, M.H.; Hii, I.M.; Lee, Y.L.; Ho, M.W.; Liu, C.E.; Chen, Y.H.; et al. High rates of misidentification of uncommon Candida species causing bloodstream infections using conventional phenotypic methods. J. Formos. Med. Assoc. 2021, 120, 1179–1187.
- 21. Mirza, A.; Senol, E.; Kalkanci, A. Epidemiology and risk factors of candidemia among hospitalized patients in a Turkish tertiary care hospital. Clin. Lab. 2022, 68.
- 22. Sathi, F.A.; Alam, M.M.; Haque, N.; Khan, M.J.A.; Mamun, A.A.; Hossain, T.; Chowdhury, C.S.; Islam, M.N.; Ferdaus, S.J.; Sultana, M. An alarming rise of candidemia caused by non-albicans Candida species in intensive care unit in Mymensingh, Bangladesh. Mymensingh Med. 2024, 33, 671–676.
- 23. Corzo-Leon, D.E.; Peacock, M.; Rodriguez-Zulueta, P.; Salazar-Tamayo, G.J.; MacCallum, D.M. General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation. Med. Mycol. 2021, 59, 664–671.
- 24. Kerai, A.; Doshi, S.; Laleker, A.; Majumdar, A. Fungal foe and mechanical hearts: A retrospective case series on Candida auris bloodstream infection with left ventricular assist devices. Open Forum Infect. Dis. 2024, 11, ofae286.
- 25. Cabanilla, M.G.; Villalobos, N. A successful daptomycin and micafungin dosing strategy in veno-venous ECMO and continuous renal replacement. J. Clin. Pharm. Ther. 2022, 47, 251–253.
- 26. Bartolo, C.; Hall, V.; Friedman, N.D.; Lanyon, C.; Fuller, A.; Morrissey, C.O.; Athan, E. Bittersweet: Infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: Two case reports. BMC Infect. Dis. 2021, 21, 284.
- 27. Rahimli, L.; Salmanton-García, J.; Kasper, P.; Simon, M.; Cornely, O.A.; Stemler, J. Necrotizing pancreatitis with invasive candidiasis and candidemia due to Candida albicans and pan-echinocandin-resistant Candidaglabrata. Med. Mycol. Case Rep. 2024, 43, 100636.
- 28. Rodríguez de la Garza, P.; Cruz-de la Cruz, C.; Bejarano, J.I.C.; Romo, A.E.L.; Delgado, J.V.; Ramos, B.A.; Martínez Neira, M.N.; Siller Rodríguez, D.; Sánchez Rodríguez, H.M.; Rangel Selvera, O.A. A multicentric outbreak of Candida auris in Mexico: 2020 to 2023. Am. J. Infect. Control 2024, 52, 1384–1389.
- 29. Vazquez, J.A.; Pappas, P.G.; Boffard, K.; Paruk, F.; Bien, P.A.; Tawadrous, M.; Ople, E.; Wedel, P.; Oborska, I.; Hodges, M.R. Clinical Efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: Results from a phase 2 trial. Antimicrob. Agents Chemother. 2023, 67, e0141922.
- 30. Randazza, O.; Erickson, K.; Denmeade, T.; Luther, V.; Palavecino, E.; Beardsley, J. Treatment of Candida nivariensis blood stream infection with oral isavuconazole. Cureus 2022, 14, e32137.
- 31. Griffith, E.M.; Marsalisi, C.; Verdecia, J.; Buchanan, S.R.; Goulart, M.A. Recurrent fungemia due to Candida auris. Cureus 2024, 16, e62478.
- 32. Lingas, E.; Lucio Paredes, M.D.M.; Jahan, M.; Bathina, P.; Dahdouh, M. A Case of Candida auris candidemia in an immunocompetent traumatic brain injury patient post ventriculoperitoneal shunt and peripherally inserted central catheter line. Cureus 2020, 12, e8850.
- 33. Xie, O.; Streitberg, R.; Hughes, C.; Stuart, R.; Graham, M. Candida duobushaemulonii sepsis and Candida auris co-isolation following hospitalisation in Vietnam. Pathology 2020, 52, 590–591.
- 34. Katsiari, M.; Nikolaou, C.; Palla, E.; Theodoridou, K.; Tsakris, A.; Vrioni, G. Impact of Candida auris on critically ill patients: A three-year observational study in a Greek intensive care unit. Pathogens 2025, 14, 328.
- 35. Rimoldi, S.G.; Nodari, R.; Rizzo, A.; Tamoni, A.; Longobardi, C.; Pagani, C.; Grosso, S.; Salari., F.; Galimberti, L.; Olivieri, P. First imported case of Candida auris infection in Milan, Italy: Genomic characterisation. Infection 2024, 52, 1633–1638.
- 36. Stolfa, S.; Caggiano, G.; Ronga, L.; Dalfino, L.; Centrone, F.; Sallustio, A.; Sacco, D.; Mosca, A.; Stufano, M.; Saracino, A.; et al. First case of Candida auris Sepsis in Southern Italy: Antifungal susceptibility and genomic characterisation of a difficult-to-treat emerging yeast. Microorganisms 2024, 12, 1962.
- 37. Reque, J.; Arlandis, R.; Panizo, N.; Pascual, M.J.; Perez-Alba, A. Candida auris invasive infection after kidney transplantation. Case Rep. Nephrol. 2022, 2022, 6007607.
- 38. Apsemidou, A.; Füller, M.A.; Idelevich, E.A.; Kurzai, O.; Tragiannidis, A.; Groll, A.H. Candida lusitaniae breakthrough fungemia in an immuno-compromised adolescent: Case report and review of the literature. J. Fungi 2020, 6, 380.
- 39. Mnichowska-Polanowska, M.; Adamowicz, M.; Wojciechowska-Koszko, I.; Kisiel, A.; Wojciuk, B.; Jarosz, K.; Dolegowska, B. Molecular investigation of the fatal bloodstream Candida orthopsilosis infection case following gastrectomy. Int. J. Mol. Sci. 2023, 24, 6541.
- 40. Tsai, Y.T.; Lu, P.L.; Tang, H.J.; Huang, C.H.; Hung, W.C.; Tseng, Y.T.; Lee, K.-M.; Lin, S.-Y. The first invasive Candida auris infection in Taiwan. Emer. Microbes Infect. 2022, 11, 1867–1875.
- 41. Ohashi, Y.; Matono, T.; Suzuki, S.; Yoshino, S.; Alshahni, M.M.; Komori, A.; Makimura, K. The first case of clade I Candida auris candidemia in a patient with COVID-19 in Japan. J. Infect. Chemother. 2023, 29, 713–717.
- 42. Murata, S.; Mimura, K.; Kawamura, T.; Saito, H.; Ohno, H.; Tsujii, E.; Shinohara, T.; Miyazaki, Y.; Ohki, T. Bloodstream infection caused by Wickerhamiella pararugosa in a patient with intestinal obstruction: A case report. J. Infect. Chemother Off. J. Jpn. Soc. Chemother. 2024, 30, 942–945.
- 43. Xu, Z.; Zhang, L.; Han, R.; Ding, C.; Shou, H.; Duan, X.; Zhang, S. A candidemia case caused by a novel drug-resistant Candida auris with the Y132F mutation in Erg11 in Mainland China. Infect. Drug Resist. 2023, 16, 3065–3072.
- 44. Aboutalebian, S.; Nikmanesh, B.; Mohammadpour, M.; Charsizadeh, A.; Mirhend, H. Candida palmioleophila candidemia and bacterial co-infection in a 3-month-old infant with biliary atresia. Front. Cell Infect. Microbiol. 2023, 13, 1277607.
- 45. Awada, B.; Alam, W.; Chalfoun, M.; Araj, G.; Bizri, A.R. COVID-19 and Candida duobushaemulonii superinfection: A case report. J. Mycol. Med. 2021, 31, 101168.
- 46. Alashqar, M.B.; Alabdan, L.; Khan, M.; Almakadma, A.H.; Almustanyir, S. A case report of a Candida auris infection in Saudi Arabia. Cureus 2021, 13, e15240.
- 47. Mirhendi, H.; Charsizadeh, A.; Aboutalebian, S.; Mohammadpour, M.; Nikmanesh, B.; de Groot, T.; Meis, J.F.; Badali, H. South Asian (Clade I) Candida auris meningitis in a paediatric patient in Iran with a review of the literature. Mycoses 2022, 65, 134–139.
- 48. Mallick, D.C.; Kaushik, N.; Goyal, L.; Mallick, L.; Singh, P. A Comprehensive Review of Candidemia and Invasive Candidiasis in Adults: Focus on the Emerging Multidrug-Resistant Fungus Candida auris. Diseases 2025, 13, 93. [
- 49. Li, Y.; Gu, C.; Yang, Y.; Ding, Y.; Ye, C.; Tang, M.; Liu, J.; Zeng, Z. Epidemiology, antifungal susceptibility, risk factors, and mortality of persistent candidemia in adult patients in China: A 6-year multicenter retrospective study. BMC Infect. Dis. 2023, 23, 369.
- 50. Zeng, Z.; Ding, Y.; Tian, G.; Yang, K.; Deng, J.; Li, G.; Liu, J. A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China. Antimicrob. Resist. Infect. Control 2020, 9, 133.
- 51. Zeeshan, M.; Memon, S.; Malick, A.; Naqvi, S.F.; Farooqi, J.; Ghanchi, N.K.; Jabeen, K. Fluconazole-resistant Candida parapsilosis complex candidemia and analysis of mutations in the ERG11 gene from Pakistan. Mycoses 2024, 67, e13677.
- 52. Salmanton-García, J.; Cornely, O.A.; Stemler, J.; Barać, A.; Steinmann, J.; Siváková, A.; Akalin, E.H.; Arikan-Akdagli, S.; Loughlin, L.; Toscano, C.; et al. Attributable mortality of candidemia—Results from the ECMM Candida III multinational European Observational Cohort Study. J. Infect. 2024, 89, 106229.
- 53. Khan, Z.; Ahmad, S.; Al-Sweih, N.; Mokaddas, E.; Al-Banwan, K.; Alfouzan, W.; Al-Obaid, I.; Al-Obaid, K.; Asadzadeh, M.; Jeragh, A.; et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS ONE 2019, 14, e0216250.
- 54. Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin. Microbiol. Infect. 2014, 20 (Suppl. 6), 5–10.
- 55. Lamba, M.; Sharma, D.; Sharma, R.; Vyas, A.; Mamoria, V. To study the profile of Candida isolates and antifungal susceptibility pattern of neonatal sepsis in a tertiary care hospital of North India. J. Matern. Fetal Neonatal Med. 2021, 34, 2655–2659.
- 56. Subba, S.H.; Sharma, T.D.; Dopthapa, Y.P.; Bhutia, U.G.N.; Sharma, R. Candida glabrata meningitis in a patient with newly diagnosed acquired immunodeficiency syndrome from Sikkim, India. Curr. Med. Mycol. 2024, 10, e2024.345242.1542.
- 57. Najafzadeh, M.J.; Shaban, T.; Zarrinfar, H.; Sedaghat, A.; Hosseinikargar, N.; Berenji, F.; Jalali, M.; Lackner, M.; James, J.E.; Iikit, M. COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Med. Mycol. 2024, 62, myae031.
- 58. Arastehfar, A.; Hilmioğlu-Polat, S.; Daneshnia, F.; Hafez, A.; Salehi, M.; Polat, F.; Yasar, M.; Arslan, N.; Hosbul, T.; Unal, N.; et al. Recent increase in the prevalence of fluconazole-non-susceptible Candida tropicalis blood isolates in Turkey: Clinical implication of azole-non-susceptible and fluconazole tolerant phenotypes and genotyping. Front. Microbiol. 2020, 11, 587278.
- 59. Ponta, G.; Morena, V.; Strano, M.; Molteni, C.; Pontiggia, S.; Cavalli, E.M.; Grancini, A.; Mauri, C.; Castagna, A.; Galanti, A.; et al. Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: Two cases from Lecco Hospital (Italy). Antimicrob. Agents Chemother. 2024, 68, e0075024.
- 60. Trovato, L.; Bongiorno, D.; Calvo, M.; Migliorisi, G.; Boraccino, A.; Musso, N.; Oliveri, S.; Stefani, S.; Scalia, G. Resistance to echinocandins complicates a case of Candida albicans bloodstream infection: A case report. J. Fungi 2021, 7, 405.
- 61. Teixeira da Silva, F.; Cardoso, F.S.; Esteves, A.; Carvalho, J.; Maia, R. Relapsing Candida parapsilosis endocarditis with septic embolization: A case report. Cureus 2021, 13, e13159.
- 62. Arastehfar, A.; Daneshnia, F.; Hafez, A.; Khodavaisy, S.; Najafzadeh, M.J.; Charsizadeh, A.; Zarrinfar, H.; Salehi, M.; Shahrabadi, Z.Z.; Sasani, E. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med. Mycol. 2020, 58, 766–773.
- 63. Alghamdi, A.; Oravec, T.; Nishi, C.; Eckbo, E.; Marcon, K.; Wright, A.; Mah, A.; White, J.; Nevill, T.; Belga, S. Severe hypercalcemia as a result of disseminated Candida krusei infection. Int. J. Infect. Dis. 2024, 140, 110–112.
- 64. Prabhudas-Strycker, K.K.; Butt, S.; Reddy, M.T. Candida tropicalis endocarditis successfully treated with AngioVac and micafungin followed by long-term isavuconazole suppression. IDCases 2020, 21, e00889.
- 65. Paucar-Miranda, C.J.; Sandoval-Ahumada, R.E.; López-Martínez, R.L.; Terrel-Gutierrez, L.; Zurita-Macalapu, S.; Urcia-Ausejo, F.; Flores-León, D.; Gavilan-Chávez, R.; Quispe-Pardo, Z.; Yagui-Moscoso, M. Primer reporte de Candida auris en Perú. An. Fac. Med. 2021, 82, 56–61.
- 66. Li, Y.; Hind, C.; Furner-Pardoe, J.; Sutton, J.M.; Rahman, K.M. Understanding the mechanisms of resistance to azole antifungals in Candida species. JAC-Antimicrob. Resist. 2025, 7, dlaf106.
- 67. Pristov, K.E.; Ghannoum, M.A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 2019, 25, 792–798.
- 68. Carolus, H.; Pierson, S.; Lagrou, K.; Van Dijck, P. Anfotericin B and other polyenes: Discovery, clinical use, mode of action and drug rsistence. J. Fungi 2020, 6, 321.
- 69. Berman, J.; Krysan, D.J. Drug resistance and tolerance in fungi. Nat. Rev. Microbiol. 2020, 18, 539.
- 70. Czajka, K.M.; Venkataraman, K.; Brabant-Kirwan, D.; Santi, S.A.; Verschoor, C.; Appanna, V.D.; Singh, R.; Saunders, D.P.; Tharmalingam, S. Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species. Cells 2023, 12, 2655.
- 71. Wurster, S.; Albert, N.D.; Kontoyiannis, D.P. Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model. mSphere 2022, 7, e00817–e00821.
- 72. Pathakumari, B.; Liu, W.; Wang, Q.; Kong, X.; Liang, G.; Chokkakula, S.; Pathakamuri, V.; Nunna, V. Comparative Evaluation of Candida Species-Specific T-Cell Immune Response in Human Peripheral Blood Mononuclear Cells. Biomedicines 2024, 12, 1487.
- 73. Carey, B.; Lambourne, J.; Porter, S.; Hodgson, T. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1. Oral Dis. 2019, 25, 684–692.
- 74. Okada, S.; Markle, J.G.; Deenick, E.K.; Mele, F.; Averbuch, D.; Lagos, M. Impairment of immunity to Candida and Mycobacterium in humans with bi allelic RORC mutations. Science 2015, 349, 606–613.
- 75. Smeekens, S.P.; Plantinga, T.S.; van de Veerdonk, F.L.; Heinhuis, B.; Hoischen, A.; Joosten, L.A. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS ONE 2011, 6, e29248.
- 76. Zaongo, S.D.; Jing, O.; Stéphane, I.; Xin, Z.; Vijay, H.; Hongjuan, C.; Routy, J.-P.; Chen, Y. Candida albicans can foster gut dysbiosis and systemic inflammation during HIV infection. Gut Microbes 2023, 15, 2167171.
- 77. Savage, H.P.; Bays, D.J.; Tiffany, C.R.; Gonzalez, M.A.F.; Bejarano, E.J.; Carvalho, T.P.; Luo, Z.; Masson, H.L.P.; Nguyen, H.; Santos, R.L.; et al. Epithelial hypoxia maintains colonization resistance against Candida albicans. Cell Host Microbe 2024, 32, 1103–1113.e1106.
- 78. Guinan, J.; Wang, S.; Hazbun, T.R.; Yadav, H.; Thangamani, S. Antibiotic-induced decreases in the levels of microbial-derived short-chain fatty acids correlate with increased gastrointestinal colonization of Candida albicans. Sci. Rep. 2019, 9, 8872.
- 79. Huang, D.; Li, H.; Lin, Y.; Lin, J.; Li, C.; Kuang, Y.; Zhou, W.; Huang, B.; Wang, P. Antibiotic-induced depletion of Clostridium species increases the risk of secondary fungal infections in preterm infants. Front. Cell. Infect. Microbiol. 2022, 12, 981823.
- 80. Bromuro, C.; Posteraro, B.; Murri, R.; Fantoni, M.; Tumbarello, M.; Sanguinetti, M.; Dattilo, R.; Cauda, R.; Cassone, A.; Torosantucci, A. Identification of two anti Candida antibodies associated with the survival of patients with candidemia. mBio 2024, 15, e02769-23.
- 81. Sari, N.; Yanik Yalçin, T.; Erol, Ç.; Kurt Azap, Ö.; Arslan, H.; Karakaya, E.; Sezgin, A.; Haberal, M. Evaluation of Candidemia in Solid-Organ Transplant Recipients. Exp. Clin. Transplant. 2024, 22, 160–166.
- 82. Marinelli, T.; Pennington, K.M.; Hamandi, B.; Donahoe, L.; Rotstein, C.; Martinu, T.; Husain, S. Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis. Transpl. Infect. Dis. 2022, 24, e13812.
- 83. Puel, A. Human inborn errors of immunity underlying superficial or invasive candidiasis. Hum. Genet. 2020, 139, 1011–1022.
- 84. Silvester, E.J.; Watanabe, M.M.Y.; Pittet, L.F.; Boast, A.; Bryant, P.A.; Haeusler, G.M.; Daley, A.J.; Curtis, N.; Gwee, A. Candidemia in Children: A 16-year Longitudinal Epidemiologic Study. Pediatr. Infect. Dis. J. 2021, 40, 537–543.
- 85. Keighley, C.L.; Pope, A.; Marriott, D.J.E.; Chapman, B.; Bak, N.; Daveson, K. Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses 2021, 64, 257–263.
- 86. Rodrigues, C.F.; Rodrigues, M.E.; Henriques, M. Candida sp. Infections in Patients with Diabetes Mellitus. J. Clin. Med. 2019, 8, 76
- 87. Quiros-Roldan, E.; Sottini, A.; Natali, P.G.; Imberti, L. The Impact of Immune System Aging on Infectious Diseases. Microorganisms 2024, 12, 775.
- 88. Hesstvedt, L.; Gaustad, P.; Müller, F.; Torp Andersen, C.; Brunborg, C.; Mylvaganam, H.; leiva, R.A.; Berdal, J.E.; Ranheim, T.E.; Johnsen, B.O.; et al. The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infect. Dis. 2019, 51, 425–434.
- 89. Nascimento, T.; Inácio, J.; Guerreiro, D.; Patrício, P.; Proença, L.; Toscano, C.; Diaz, P.; Barroso, H. Insights into Candida Colonization in Intensive Care Unit Patients: A Prospective Multicenter Study. J. Fungi 2024, 10, 378.
- 90. Bassetti, M.; Vena, A.; Giacobbe, D.R.; Trucchi, C.; Ansaldi, F.; Antonelli, M.; Adamkova, V.; Alicino, C.; Almyroudi, M.-P.; Atchade, E.; et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infect. Dis. Ther. 2022, 11, 827–840.
- 91. Thomas-Rüddel, D.O.; Schlattmann, P.; Pletz, M.; Kurzai, O.; Bloos, F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022, 161, 345–355.
- 92. Dougherty, J.; Turner, N.A.; Yarrington, M.E.; Shaefer Spires, S.; Rebekah, W.M.; Alexander, B.D.; Park, L.P.; Johnson, M.D. Cumulative Antibiotic Exposure and Risk for Candidemia. Open Forum Infect. Dis. 2022, 9, ofac492.099.
- 93. Jung, P.; Mischo, C.E.; Gunaratnam, G.; Spengler, C.; Becker, S.L.; Hube, B.; Jacobs, K.; Bischoff, M. Candida albicans adhesion to central venous catheters: Impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. Virulence 2020, 11, 1453–1465.
- 94. Huang, L.; Li, S.; Jiang, R.; Lei, S.; Wu, J.; Huang, L.; Zhu, M. Glucocorticoid use and parenteral nutrition are risk factors for catheter-related Candida bloodstream infection: A retrospective study. Asian Biomed. (Res. Rev. News) 2024, 18, 109–115.
- 95. Malinovská, Z.; Čonková, E.; Váczi, P. Biofilm Formation in Medically Important Candida Species. J. Fungi 2023, 9, 955.
- 96. Gulati, M.; Nobile, C.J. Candida albicans biofilms: Development, regulation, and molecular mechanisms. Microbes Infect. 2016, 18, 310–321.
- 97. Oliva, A.; Venditti, M. Candidiasis invasiva en cirugía. In Infecciones en Cirugía. Actualizaciones en Cirugía; Bartoli, S., Cortese, F., Sartelli, M., Sganga, G., Eds.; Springer: Cham, Switzerland, 2025.
- 98. Meng, Y.; Kang, M.; Li, D.; Wang, T.; Kuang, Z.; Ma, Y. Performance of a new Candida anti-mannan IgM and IgG assays in the diagnosis of candidemia. Rev. Inst. Med. Trop. Sao Paulo 2020, 62, e25.
- 99. Barantsevich, N.; Barantsevich, E. Diagnosis and Treatment of Invasive Candidiasis. Antibiotics 2022, 11, 718.
- 100. Montagna, M.T.; Coretti, C.; Rella, A.; Barbuti, G.; Manca, F.; Montagna, O.; Laforgia, N.; Caggiano, G. The role of procalcitonin in neonatal intensive care unit patients with candidemia. Folia Microbiol. 2013, 58, 27–31.
- 101. Cortegiani, A.; Misseri, G.; Ippolito, M.; Bassetti, M.; Giarratano, A.; Martin-Loeches, I.; Einav, S. Procalcitonin levels in candidemia versus bacteremia: A systematic review. Crit. Care 2019, 23, 190.
- 102. Chen, B.; Li, W.; Pang, Y.; Zhang, N.; Bian, S.; Liu, C.; Yang, Z.; Jiang, Y.; Li, R.; Xie, Y.; et al. Rapid detection of fungi from blood samples of patients with candidemia using modified calcofluor white stain. J. Microbiol. Methods 2021, 184, 106202.
- 103. Kaur, H.; Kanaujia, R.; Singh, S.; Kajal, K.; Jayashree, M.; Peter, N.J.; Verma, S.; Gupta, M.; Ray, P.; Ghosh, A.; et al. Clinical utility of time to positivity of blood cultures in cases of fungaemia: A prospective study. Indian. J. Med. Microbiol. 2023, 43, 85–89
- 104. Keighley, C.; Pope, A.L.; Marriott, D.; Chen, S.C.; Slavin, M.A.; Australia and New Zealand Mycoses Interest Group. Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality. Med. Mycol. 2023, 61, myad028.
- 105. Bonfim-Mendonça, P.d.S.; Fiorini, A.; Shinobu-Mesquita, C.S.; Baeza, L.C.; Fernandez, M.A.; Svidzinski, T.I. Molecular typing of Candida albicans isolates from hospitalized patients. Rev. Inst. Med. Trop. 2013, 55, 385–391.
- 106. Camp, I.; Spettel, K.; Willinger, B. Molecular Methods for the Diagnosis of Invasive Candidiasis. J. Fungi 2020, 6, 101.
- 107. Mesini, A.; Mikulska, M.; Giacobbe, D.R.; Del Puente, F.; Gandolfo, N.; Codda, G.; Orsi, A.; Tassinari, F.; Beltramini, S.; Marchese, A.; et al. Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. Mycoses 2020, 63, 361–368.
- 108. Daneshnia, F.; Hilmioğlu-Polat, S.; Ilkit, M.; Fuentes, D.; Lombardi, L.; Binder, U.; Scheler, J.; Hagen, F.; Mansour, M.K.; Butler, G.; et al. Whole-genome sequencing confirms a persistent candidaemia clonal outbreak due to multidrug-resistant Candida parapsilosis. J. Antimicrob. Chemother. 2023, 78, 1488–1494.
- 109. Monday, L.M.; Parraga Acosta, T.; Alangaden, G. T2Candida for the Diagnosis and Management of Invasive Candida Infections. J. Fungi 2021, 7, 178.
- 110. Park, K.; Huh, J.W.; Choi, S.H.; Sung, H.; Kim, M.N. Clinical evaluation of the T2Candida assay for the rapid diagnosis of candidemia. Diagn. Microbiol. Infect. Dis. 2024, 110, 116406.
- 111. Krifors, A.; Ullberg, M.; Castegren, M.; Petersson, J.; Sparrelid, E.; Hammarström, H.; Sjolin, J.; Ozenci, V.; Blennow, O. T2Candida Assay in the Diagnosis of Intraabdominal Candidiasis: A Prospective Multicenter Study. J. Fungi 2022, 8, 86.
- 112. Camp, I.; Füszl, A.; Selitsch, B.; Kröckel, I.; Kovac, K.; Wahrmann, M.; Steinlechner, B.; Weber, J.; Schellongowski, P.; Zauner, C.; et al. Is the T2MR Candida Panel a suitable alternative to the SeptiFast for the rapid diagnosis of candidemia in routine clinical practice? Clin. Microbiol. Infect. 2024, 30, 816–821.
- 113. Park, B.; Oh, E.H.; Won, E.J.; Kang, J.; Jin, D.; Yoo, C.; Park, J.; Sung, H.; Kim, M.-N. Detection of clinically relevant Candida species from positive blood cultures using a novel sample-to-answer molecular assay. Sci. Rep. 2025, 15, 5417.
- 114. Balaji, L.; Manoharan, H.; Prabhakaran, N.; Manivannan, N. Time-to-Positivity for Candida in Bloodstream Infections: Prognostic Implications for Mortality. Cureus 2024, 16, e66364.
- 115. Aziz, H.S.A.; Ismail, D.K.; Mohammed, N.S.A.; Elgendy, M.O.; Bassiouny, D.M. Distribution and antifungal susceptibility profiles of Candida species isolated from candidemia patients admitted to Egyptian tertiary hospitals: A cross-sectional study. BMC Infect. Dis. 2024, 24, 1177.
- 116. de Souza, Â.C.; Pereira, D.C.; Barth, P.O.; Roesch, E.W.; Lutz, L.; Aquino, V.R.; Goldani, L.Z. Rapid identification, fluconazole and micafungin susceptibility testing of Candida species from blood culture by a short incubation method. Diagn. Microbiol. Infect. Dis. 2024, 109, 116271.
- 117. Meawed, T.E.; AlNakeera, A.M.; Attia, O.; Hassan, N.A.M.; Anis, R.H. Candida auris central line-associated blood stream infection in critically ill patients: The worst end of a bad scenario. Int. Microbiol. 2025, 28, 377–383.
- 118. Peter Donnelly, J.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376.
- 119. Dobiáš, R.; Káňová, M.; Petejová, N.; Pisti, Š.K.; Bocek, R.; Krejčí, E.; Struzkoca, H.; Cachová, M.; Tomasková, H.; Hamal, P.; et al. Combined Use of Presepsin and (1, 3)-β-D-glucan as Biomarkers for Diagnosing Candida Sepsis and Monitoring the Effectiveness of Treatment in Critically Ill Patients. J. Fungi 2022, 8, 308.
- 120. Zacharioudakis, I.M.; Zervou, F.N.; Marsh, K.; Siegfried, J.; Yang, J.; Decano, A.; Dubrovskaya, Y.; Mazo, D.; Aguero-Rosenfeld, M. Utility of incorporation of beta-D-glucan and T2Candida testing for diagnosis and treatment of candidemia. Diagn. Microbiol. Infect. Dis. 2024, 108, 116107.
- 121. Kinet-Poleur, A.; Deckers, C.; Saad Albichr, I.; Bogaerts, P.; Honoré, P.M.; Bulpa, P.; Ausselet, N.; Foret, F.; Kidd, F.; Huang, T.-D.; et al. Evaluation of Serum Biomarkers for Improved Diagnosis of Candidemia. J. Fungi 2025, 11, 224.
- 122. Lorenzo-Villegas, D.L.; Gohil, N.V.; Lamo, P.; Gurajala, S.; Bagiu, I.C.; Vulcanescu, D.D.; Horhat, F.G.; Sorop, V.B.; Diaconu, M.; Sorop, M.I.; et al. Innovative Biosensing Approaches for Swift Identification of Candida Species, Intrusive Pathogenic Organisms. Life 2023, 13, 2099.
- 123. Martin-Loeches, I.; Antonelli, M.; Cuenca-Estrella, M.; Dimopoulos, G.; Einav, S.; De Waele, J.J.; Garnacho-Montero, J.; Kanj, S.S.; Machado, F.R.; Montravers, P.; et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019, 45, 789–805.
- 124. Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2015, 62, e1–e50.
- 125. Aydin, S.; Derin, O.; Sahin, M.; Dinleyici, R.; Yilmaz, M.; Ceylan, B.; Tosun, A.I.; Ozturk, R.; Mert, A. Epidemiology of Nosocomial Candidemia, Mortality, and Antifungal Resistance: 7-Year Experience in Turkey. Jpn. J. Infect. Dis. 2022, 75, 597–603.
- 126. Horn, D.L.; Neofytos, D.; Anaissie, E.J.; Fishman, J.A.; Steinbach, W.J.; Olyaei, A.J.; Marr, K.A.; Pfaller, M.A.; Chang, C.-H.; Webster, K.M. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009, 48, 1695–1703.
- 127. Fang, X.; Su, C.; Luo, Y.; Pan, K.; Lin, J.; Song, Y.; Huang, Y.; Hu, X.; Shen, Z. Risk factors associated with short-term mortality in patients with candidemia and the predictive value of serum cytokine level. Cytokine 2025, 185, 156803.
- 128. Liu, F.; Shao, X.; Dong, Z.; Tang, K.; Zhong, L.; Xu, W.; Chen, Z.; Zheng, C.; Zhang, K.; Cai, J.; et al. Clinical characteristics and prognostic risk factors of candidemia in non-neutropenic patients: A retrospective cohort study. Eur. J. Clin. Microbiol. Infect. Dis. 2023, 42, 1389–1394.
- 129. Suh, J.W.; Kim, M.J.; Kim, J.H. Risk factors of septic shock development and thirty-day mortality with a predictive model in adult candidemia patients in intensive care units. Infect. Dis. 2021, 53, 908–919.
- 130. Kutlu, M.; Sayın-Kutlu, S.; Alp-Çavuş, S.; Öztürk, Ş.B.; Taşbakan, M.; Özhak, B.; Kaya, O.; Kutsoylu, O.E.; Senol-Akar, S.; Turhan, O.; et al. Mortality-associated factors of candidemia: A multi-center prospective cohort in Turkey. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 597–607.
- 131. Hoenigl, M.; Salmanton-García, J.; Egger, M.; Gangneux, J.P.; Bicanic, T.; Arikan-Akdagli, S.; Alastruey-Izquierdo, A.; Klimko, N.; Barac, A.; Ozenci, V.; et al. Guideline adherence and survival of patients with candidaemia in Europe: Results from the ECMM Candida III multinational European observational cohort study. Lancet Infect. Dis. 2023, 23, 751–761.
- 132. Sahoo, B.; Goyal, R.; Dutta, S.; Joshi, P.; Sanyal, K. Candida albicans: Insights into the Biology and Experimental Innovations of a Commonly Isolated Human Fungal Pathogen. ACS Infect. Dis. 2025, 11, 1780–1815.
- 133. Murphy, S.E.; Bicanic, T. Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. Front. Cell. Infect. Microbiol. 2021, 11, 759408.
- 134. Kollef, M.; Micek, S.; Hampton, N.; Doherty, J.A.; Kumar, A. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin. Infect. Dis. 2012, 54, 1739–1746.
- 135. Rouzé, A.; Loridant, S.; Poissy, J.; Dervaux, B.; Sendid, B.; Cornu, M.; Nseir, S.; Study Group S-TAFE. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: A randomized controlled trial. Intensive Care Med. 2017, 43, 1668–1677.
- 136. Paiva, J.A.; Charles, P.E. Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time? Intensive Care Med. 2017, 43, 1889–1891.
- 137. Healy, C.M.; Baker, C.J.; Zaccaria, E.; Campbell, J.R. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr. 2005, 147, 166–171.
- 138. Kaufman, D.; Boyle, R.; Hazen, K.C.; Patrie, J.T.; Robinson, M.; Grossman, L.B. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J. Pediatr. 2005, 147, 172–179.
- 139. Cokro, F.; Yolanda, L.; Caroline, S.; Studi Farmasi, P.; Kedokteran dan Ilmu Kesehatan, F. Fluconazole Effectiveness in Preventing Invasive Fungal Infection in Very Low Birth Weight Infants: Systematic Review and Meta-analysis (Efektivitas Flukonazol dalam Mencegah Infeksi Jamur Invasif pada Bayi dengan Berat Lahir Sangat Rendah: Tinjauan Sistematis dan Meta-analisis). J. Ilmu Kefarmasian Indonesia. 2022, 20, 14–22.
- 140. Lona-Reyes, J.C.; Gómez-Ruiz, L.M.; Cordero-Zamora, A.; Cortés-González, S.I.; Quiles-Corona, M.; Pérez-Ramírez, R.O.; Pinto-Macedo, H. Incidence and factors associated with invasive candidiasis in a neonatal intensive care unit in Mexico. An. Pediatr. (Engl. Ed.) 2022, 97, 79–86.
- 141. Estagnasié, C.; Mohr, C.; Kamus, L.; Zunic, P.; Chirpaz, E.; Moiton, M.P.; Lagrange-Xelot, M. Invasive fungal infections in patients with haematological malignancies at the University Hospital of Reunion Island (2018–2022): An observational study. Med. Mycol. 2024, 62, myae102.
- 142. Cornely, O.A.; Maertens, J.; Winston, D.J.; Perfect, J.; Ullmann, A.J.; Walsh, T.J.; Helfgott, D.; Holowiecki, J.; Stockelberg, D.; Goh, Y.-T.; et al. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. N. Engl. J. Med. 2007, 356, 348-59.
- 143. Boutin, C.A.; Durocher, F.; Beauchemin, S.; Ziegler, D.; Chakra, C.N.A.; Dufresne, S.F. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. Clin. Infect. Dis. 2024, 79, 151–160.
- 144. Rausch, C.R.; DiPippo, A.J.; Jiang, Y.; DiNardo, C.D.; Kadia, T.; Maiti, A.; Montalban-Bravo, G.; Ravandi, F. Kontoyiannis, D.P. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients with Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clin. Infect. Dis. 2022, 75, 1503–1510.
- 145. Calle-Miguel, L.; Garrido-Colino, C.; Santiago-García, B.; Moreno Santos, M.P.; Gonzalo Pascual, H.; Ponce Salas, B.; Beléndez Bieler, C.; Navarro Gómez, M.; Guinea Ortega, J.; Rincón-López, E.M. Changes in the epidemiology of invasive fungal disease in a Pediatric Hematology and Oncology Unit: The relevance of breakthrough infections. BMC Infect. Dis. 2023, 23, 348.
- 146. Cornely, O.A.; Sprute, R.; Bassetti, M.; Chen, S.C.A.; Groll, A.H.; Kurzai, O.; Lass-Florl, C.; Ostrosky-Zeichner, L.; Rautemaa-Richardson, R.; Revathia, G.; et al. Global guideline for the diagnosis and management of candidiasis: An initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect. Dis. 2025, 25, e280–e293.
- 147. Aslam, S.; Rotstein, C. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transpl. 2019, 33, e13623.
- 148. Carugati, M.; Arif, S.; Yarrington, M.E.; King, L.Y.; Harris, M.; Evans, K.; Barbas, A.S.; Sudan, D.L.; Perfect, J.R.; Miller, R.A.; et al. Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery. Antimicrob. Agents Chemother. 2024, 68, e0127923.
- 149. López-Medrano, F.; de la Espada, M.M.; Asín, M.A.P.; Fernández-Ruiz, M.; Herrero-Martínez, J.M.; Alonso-Carrillo, J.; San Juan, R.; Rodríguez-Goncer, I.; Andrés, A.; González, E.; et al. Fluconazole versus micafungin for initial antifungal prophylaxis against Candida in pancreas transplant recipients: A comparative study of two consecutive periods. Mycoses 2022, 65, 517–525.
- 150. Bloos, F.; Held, J.; Kluge, S.; Simon, P.; Kogelmann, K.; de Heer, G.; Kuhn, S.-O.; Jarczak, D.; Motsch, J.; Hempel, G.; et al. (1 → 3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: The CandiSep randomized clinical trial. Intensive Care Med. 2022, 48, 865–875.
- 151. Erb, T.; Mihai, S.; Strauß, R.; Herbst, L.; Castellanos, I.; Diesch, K.; Cipa, F.; Bihlmaier, K.; Lang, A.-K.; Ganslmayer, M.; et al. β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: A randomized controlled study. Antimicrob. Agents Chemother. 2023, 67, e0072523.
- 152. Tissot, F.; Agrawal, S.; Pagano, L.; Petrikkos, G.; Groll, A.H.; Skiada, A.; Lass-Florl, C.; Calandra, T.; Viscoli, C.; Herbrecht, R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017, 102, 433–444.
- 153. Keighley, C.; Cooley, L.; Morris, A.J.; Ritchie, D.; Clark, J.E.; Boan, P.; Worth, L.J.; Australasian Antifungal Guidelines Steering Committee. Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Intern. Med. J. 2021, 51, 89–117.
- 154. Andes, D.R.; Safdar, N.; Baddley, J.W.; Playford, G.; Reboli, A.C.; Rex, J.H.; Sobel, J.D.; Pappas, P.G.; Kullberg, B.J.; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin. Infect. Dis. 2012, 54, 1110–1122.
- 155. Wolfgruber, S.; Sedik, S.; Klingspor, L.; Tortorano, A.; Gow, N.A.R.; Lagrou, K.; Gangneux, J.-P.; Maertens, J.; Meis, J.F.; Lass-Florl, C.; et al. Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV. Mycopathologia 2024, 189, 70.
- 156. Maseda, E.; Martín-Loeches, I.; Zaragoza, R.; Pemán, J.; Fortún, J.; Grau, S.; Aguilar, G.; Varela, M.; Borges, M.; Giménez, M.-J.; et al. Critical appraisal beyond clinical guidelines for intraabdominal candidiasis. Crit. Care 2023, 27, 382.
- 157. Pais, M.M.; Zaragoza, R.; Martín-Loeches, I.; Gómez-Bertomeu, F.F.; Rodríguez, A. Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review. J. Fungi 2025, 11, 362.
- 158. Kim, H.Y.; Baldelli, S.; Märtson, A.G.; Stocker, S.; Alffenaar, J.W.; Cattaneo, D.; Marriott, D.J. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther. Drug Monit. 2022, 44, 198–214.
- 159. Beyda, N.D.; John, J.; Kilic, A.; Alam, M.J.; Lasco, T.M.; Garey, K.W. FKS mutant Candida glabrata: Risk factors and outcomes in patients with candidemia. Clin. Infect. Dis. 2014, 59, 819–825.
- 160. Hoenigl, M.; Arastehfar, A.; Arendrup, M.C.; Brüggemann, R.; Carvalho, A.; Chiller, T.; Chen, S.; Egger, M.; Feys, S.; Ganneux, J.-P.; et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin. Microbiol. Rev. 2024, 37, e0007423.
- 161. Nagamizu, M.; Hotta, Y.; Noda, M.; Nakamura, D.; Hori, M.; Otsuka, Y.; Takemoto, R.; Horita, Y.; Wakita, E.; Morishita, N.; et al. Association of doses based on body constitutional parameters with the efficacy of micafungin in candidemia. J. Infect. Chemother. 2025, 31, 102654.
- 162. Alsowaida, Y.S.; Sulaiman, K.A.; Mahrous, A.J.; Alharbi, A.; Bifari, N.; Alshahrani, W.A.; Almangour, T.A.; Damfu, N.; Banamah, A.; Abu Raya, R.R.; et al. Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study. Int. J. Infect. Dis. 2024, 148, 107234.
- 163. Thompson, G.R.; Soriano, A.; Skoutelis, A.; Vazquez, J.A.; Honore, P.M.; Horcajada, J.P.; Spapen, H.; Bassetti, M.; Ostrosky-Zeichner, L.; Das, A.F.; et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin. Infect. Dis. 2021, 73, E3647–E3655.
- 164. Thompson, G.R.; Soriano, A.; Cornely, O.A.; Kullberg, B.J.; Kollef, M.; Vazquez, J.; Honore, P.M.; Bassetti, M.; Pullman, J.; Chayakulkeeree, M.; et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023, 401, 49–59.
- 165. Soriano, A.; Locke, J.B.; Cornely, O.A.; Roilides, E.; Ramos-Martinez, A.; Honoré, P.M.; Castanheira, M.; Carvalhaes, C.G.; Nseir, S.; Bassetti, M.; et al. Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: Pooled analyses of two randomized trials of rezafungin versus caspofungin. Clin. Microbiol. Infect. 2025, 31, 250–257.
- 166. Nucci, M.; Anaissie, E.; Betts, R.F.; Dupont, B.F.; Wu, C.; Buell, D.N.; Kovanda, L.; Lortholary, O. Early removal of central venous catheter in patients with candidemia does not improve outcome: Analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 2010, 51, 295–303.
- 167. Nucci, M.; Braga, P.R.; Nouér, S.A.; Anaissie, E. Time of catheter removal in candidemia and mortality. Braz. J. Infect. Dis. 2018, 22, 455–461.
- 168. Lee, Y.M.; Ryu, B.H.; Hong, S.I.; Cho, O.H.; Hong, K.W.; Bae, I.G.; Kwack, W.G.; Kim, Y.J.; Chung, E.K.; Kim, D.Y.; et al. Clinical impact of early reinsertion of a central venous catheter after catheter removal in patients with catheter-related bloodstream infections. Infect. Control. Hosp. Epidemiol. 2021, 42, 162–168.
- 169. Zuo, X.S.; Liu, Y.; Cai, X.; Zhan, L.; Hu, K. Association of different Candida species with catheter-related candidemia, and the potential antifungal treatments against their adhesion properties and biofilm-forming capabilities. J. Clin. Lab. Anal. 2021, 35, e23738.
- 170. Breazzano, M.P.; Bond, J.B.; Bearelly, S.; Kim, D.H.; Donahue, S.P.; Lum, F.; Olsen, T.W.; American Academy of Ophthalmology. American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis. Ophthalmology 2022, 129, 73–76.
- 171. Breazzano, M.P.; Day, H.R.; Bloch, K.C.; Tanaka, S.; Cherney, E.F.; Sternberg, P.; Donahue, S.P.; Bond 3rd, J.B. Utility of Ophthalmologic Screening for Patients with Candida Bloodstream Infections: A Systematic Review. JAMA Ophthalmol. 2019, 137, 698–710.
- 172. Phongkhun, K.; Pothikamjorn, T.; Srisurapanont, K.; Manothummetha, K.; Sanguankeo, A.; Thongkam, A.; Chuleerarux, N.; Leksuwankun, S.; Meejun, T.; Thanakitcharu, J.; et al. Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients with Candidemia: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2023, 76, 1738–1749.
- 173. Lehman, A.; Tessier, K.M.; Sattarova, V.; Montezuma, S.R.; Kline, S.; Erayil, S.E. Do Patients With Candidemia Need an Ophthalmologic Examination? Open Forum Infect. Dis. 2024, 11, ofae663.
- 174. Shin, S.U.; Yu, Y.H.; Kim, S.S.; Oh, T.H.; Kim, S.E.; Kim, U.J.; Kang, S.-J.; Jang, H.-C.; Park, K.-H.; Jung, S.I. Clinical characteristics and risk factors for complications of candidaemia in adults: Focus on endophthalmitis, endocarditis, and osteoarticular infections. Int. J. Infect. Dis. 2020, 93, 126–132.
- 175. Soriano, A.; Honore, P.M.; Puerta-Alcalde, P.; Garcia-Vidal, C.; Pagotto, A.; Gonçalves-Bradley, D.C.; Verweij, P.E. Invasive candidiasis: Current clinical challenges and unmet needs in adult populations. J. Antimicrob. Chemother. 2023, 78, 1569–1585.
- 176. Permpalung, N.; Sedik, S.; Pappas, P.G.; Hoenigl, M.; Ostrosky-Zeichner, L. Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis. Clin. Microbiol. Infect. 2025; in press.
- 177. Turner, R.B.; Valcarlos, E.; Won, R.; Chang, E.; Schwartz, J. Impact of infectious diseases consultation on clinical outcomes of patients with Staphylococcus aureus bacteremia in a community health system. Antimicrob. Agents Chemother. 2016, 60, 5682–5687.
- 178. Kobayashi, T.; Marra, A.R.; Schweizer, M.L.; Eyck, P.T.; Wu, C.; Alzunitan, M.; Salinas, J.L.; Siegel, M.; Farmakiotis, D.; Auwaerter, P.G.; et al. Impact of infectious disease consultation in patients with candidemia: A retrospective study, systematic literature review, and meta-analysis. Open Forum Infect. Dis. 2020, 7, ofaa270.
- 179. Lee, R.A.; Vo, D.T.; Zurko, J.C.; Griffin, R.L.; Rodriguez, J.M.; Camins, B.C. Infectious diseases consultation is associated with decreased mortality in enterococcal bloodstream infections. Open Forum Infect. Dis. 2020, 7, ofaa064.
- 180. Schmitt, S.; McQuillen, D.P.; Nahass, R.; Martinelli, L.; Rubin, M.; Schwebke, K.; Petrak, R.; Ritter, J.T.; Chansolme, D.; Slama, T.; et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin. Infect. Dis. 2014, 58, 22–28.
References
1. Mora Carpio, A.L.; Climaco, A. Candidemia. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025.
2. Lass-Flörl, C.; Kanj, S.S.; Govender, N.P.; Thompson, G.R.; Ostrosky-Zeichner, L.; Govrins, M.A. Invasive candidiasis. Nat. Rev. Dis. Prim. 2024, 10, 20.
3. McCarty, T.P.; White, C.M.; Pappas, P.G. Candidemia and Invasive Candidiasis. Infect. Dis. Clin. N. Am. 2021, 35, 389–413.
4. Uraguchi, K.; Makino, T.; Kariya, S.; Noda, Y.; Marunaka, H.; Doi, A.; Kozakura, K.; Takao, S.; Ando, M. Candidemia in patients with head and neck cancer: Mortality and a novel risk factor. Support. Care Cancer 2022, 30, 5921–5930.
5. Atiencia-Carrera, M.B.; Cabezas-Mera, F.S.; Tejera, E.; Machado, A. Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis. PLoS ONE 2022, 17, e0263522.
6. Harchand, R.; Spruijtenburg, B.; Meijer, E.F.J.; de Groot, T.; Rudramurthy, S.M.; Meis, J.F. Candida vulturna, the Next Fungal Menace? A Narrative Review. Mycoses 2025, 68, e70070.
7. Pérez-Camacho, P.M.; Vargas-Moran, C.; Torres-Canchala, L.; Ariza-Insignares, C.; Sandoval-Calle, L.M.; Gómez-Hernández, I.E.; Solís-Núñez, P.; Cedeño-Castaño, J.V.; Aguilar-González, A.M.; Patiño-Niño, J.A. Epidemiological characteristics of pediatric patients with invasive candidiasis in an intensive care unit in southwestern Colombia. Biomedica 2025, 45, 151–164.
8. Cook, A.; Ferreras-Antolin, L.; Adhisivam, B.; Ballot, D.; Berkley, J.A.; Bernaschi, P.; Carvalheriro, C.G.; Chaikittisuk, N.; Chen, Y.; Chibabhai, V. Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study. Med. Mycol. 2023, 61, myad010.
9. Brescini, L.; Mazzanti, S.; Orsetti, E.; Morroni, G.; Masucci, A.; Pocognoli, A.; Barchiesi, F. Species distribution and antifungal susceptibilities of bloodstream Candida isolates: A nine-years single center survey. J. Chemother. 2020, 32, 244–250.
10. Posteraro, B.; De Carolis, E.; Criscuolo, M.; Ballanti, S.; De Angelis, G.; Del Principe, M.I.; Delia, M.; Fracchiolla, N.; Marchesi, F.; Nadali, G. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses 2020, 63, 900–910.
11. Egger, M.; Salmanton-García, J.; Barac, A.; Gangneux, J.P.; Guegan, H.; Arsic-Arsenijevic, V.; Matos, T.; Tomazin, R.; Klimko, N.; Bassetti, M.; et al. ECMM Candida III Study Group Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III multinational European observational cohort study. Mycopathologia 2023, 188, 983–994.
12. Liu, T.; Sun, S.; Zhu, X.; Wu, H.; Sun, Z.; Peng, S. Epidemiology, clinical characteristics, and outcome in candidemia: A retrospective five-year analysis from two tertiary general hospitals. BMC Infect. Dis. 2025, 25, 512.
13. Zhang, W.; Song, X.; Wu, H.; Zheng, R. Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients. BMC Infect. Dis. 2020, 20, 506.
14. Kajihara, T.; Yahara, K.; Nagi, M.; Kitamura, N.; Hirabayashi, A.; Hosaka, Y.; Abe, M.; Miyazaki, Y.; Sugai, M. Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010–2019: A retrospective observational study based on national surveillance data. Med. Mycol. 2022, 60, myac071.
15. Doğan, Ö.; Yeşilkaya, A.; Menekşe, Ş.; Güler, Ö.; Karakoç, Ç.; Çınar, G.; Kapmaz, M.; Aydin, M.; Keske, S.; Sahin, S.; et al. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group. Int. J. Antimicrob. Agents 2020, 56, 105992.
16. Arastehfar, A.; Yazdanpanah, S.; Bakhtiari, M.; Fang, W.; Pan, W.; Mahmoudi, S.; Pakshir, K.; Daneshina, F.; Boekhout, T.; Ilkit, M.; et al. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018). Med. Mycol. 2021, 59, 422–430.
17. Szekely, J.; Rakchang, W.; Rattanaphan, P.; Kositpantawong, N. Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak. Epidemiol. Infect. 2023, 151, e146.
18. Pappas, P.G.; Vazquez, J.A.; Oren, I.; Rahav, G.; Aoun, M.; Bulpa, P.; Ben-Ami, R.; Ferrer, R.; Mccarty, T.; Thompson, G.R.; et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: Results from a Phase 2 trial. J. Antimicrob. Chemother. 2023, 78, 2471–2480.
19. Shuping, L.; Mpembe, R.; Mhlanga, M.; Naicker, S.D.; Maphanga, T.G.; Tsotetsi, E.; Wadula, J.; Velaphi, S.; Nakwa, F.; Chibabhai, V. Epidemiology of culture-confirmed candidemia among hospitalized children in South Africa, 2012–2017. Pediatr. Infect. Dis. J. 2021, 40, 730–737.
20. Huang, Y.S.; Wang, F.D.; Chen, Y.C.; Huang, Y.T.; Hsieh, M.H.; Hii, I.M.; Lee, Y.L.; Ho, M.W.; Liu, C.E.; Chen, Y.H.; et al. High rates of misidentification of uncommon Candida species causing bloodstream infections using conventional phenotypic methods. J. Formos. Med. Assoc. 2021, 120, 1179–1187.
21. Mirza, A.; Senol, E.; Kalkanci, A. Epidemiology and risk factors of candidemia among hospitalized patients in a Turkish tertiary care hospital. Clin. Lab. 2022, 68.
22. Sathi, F.A.; Alam, M.M.; Haque, N.; Khan, M.J.A.; Mamun, A.A.; Hossain, T.; Chowdhury, C.S.; Islam, M.N.; Ferdaus, S.J.; Sultana, M. An alarming rise of candidemia caused by non-albicans Candida species in intensive care unit in Mymensingh, Bangladesh. Mymensingh Med. 2024, 33, 671–676.
23. Corzo-Leon, D.E.; Peacock, M.; Rodriguez-Zulueta, P.; Salazar-Tamayo, G.J.; MacCallum, D.M. General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation. Med. Mycol. 2021, 59, 664–671.
24. Kerai, A.; Doshi, S.; Laleker, A.; Majumdar, A. Fungal foe and mechanical hearts: A retrospective case series on Candida auris bloodstream infection with left ventricular assist devices. Open Forum Infect. Dis. 2024, 11, ofae286.
25. Cabanilla, M.G.; Villalobos, N. A successful daptomycin and micafungin dosing strategy in veno-venous ECMO and continuous renal replacement. J. Clin. Pharm. Ther. 2022, 47, 251–253.
26. Bartolo, C.; Hall, V.; Friedman, N.D.; Lanyon, C.; Fuller, A.; Morrissey, C.O.; Athan, E. Bittersweet: Infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: Two case reports. BMC Infect. Dis. 2021, 21, 284.
27. Rahimli, L.; Salmanton-García, J.; Kasper, P.; Simon, M.; Cornely, O.A.; Stemler, J. Necrotizing pancreatitis with invasive candidiasis and candidemia due to Candida albicans and pan-echinocandin-resistant Candidaglabrata. Med. Mycol. Case Rep. 2024, 43, 100636.
28. Rodríguez de la Garza, P.; Cruz-de la Cruz, C.; Bejarano, J.I.C.; Romo, A.E.L.; Delgado, J.V.; Ramos, B.A.; Martínez Neira, M.N.; Siller Rodríguez, D.; Sánchez Rodríguez, H.M.; Rangel Selvera, O.A. A multicentric outbreak of Candida auris in Mexico: 2020 to 2023. Am. J. Infect. Control 2024, 52, 1384–1389.
29. Vazquez, J.A.; Pappas, P.G.; Boffard, K.; Paruk, F.; Bien, P.A.; Tawadrous, M.; Ople, E.; Wedel, P.; Oborska, I.; Hodges, M.R. Clinical Efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: Results from a phase 2 trial. Antimicrob. Agents Chemother. 2023, 67, e0141922.
30. Randazza, O.; Erickson, K.; Denmeade, T.; Luther, V.; Palavecino, E.; Beardsley, J. Treatment of Candida nivariensis blood stream infection with oral isavuconazole. Cureus 2022, 14, e32137.
31. Griffith, E.M.; Marsalisi, C.; Verdecia, J.; Buchanan, S.R.; Goulart, M.A. Recurrent fungemia due to Candida auris. Cureus 2024, 16, e62478.
32. Lingas, E.; Lucio Paredes, M.D.M.; Jahan, M.; Bathina, P.; Dahdouh, M. A Case of Candida auris candidemia in an immunocompetent traumatic brain injury patient post ventriculoperitoneal shunt and peripherally inserted central catheter line. Cureus 2020, 12, e8850.
33. Xie, O.; Streitberg, R.; Hughes, C.; Stuart, R.; Graham, M. Candida duobushaemulonii sepsis and Candida auris co-isolation following hospitalisation in Vietnam. Pathology 2020, 52, 590–591.
34. Katsiari, M.; Nikolaou, C.; Palla, E.; Theodoridou, K.; Tsakris, A.; Vrioni, G. Impact of Candida auris on critically ill patients: A three-year observational study in a Greek intensive care unit. Pathogens 2025, 14, 328.
35. Rimoldi, S.G.; Nodari, R.; Rizzo, A.; Tamoni, A.; Longobardi, C.; Pagani, C.; Grosso, S.; Salari., F.; Galimberti, L.; Olivieri, P. First imported case of Candida auris infection in Milan, Italy: Genomic characterisation. Infection 2024, 52, 1633–1638.
36. Stolfa, S.; Caggiano, G.; Ronga, L.; Dalfino, L.; Centrone, F.; Sallustio, A.; Sacco, D.; Mosca, A.; Stufano, M.; Saracino, A.; et al. First case of Candida auris Sepsis in Southern Italy: Antifungal susceptibility and genomic characterisation of a difficult-to-treat emerging yeast. Microorganisms 2024, 12, 1962.
37. Reque, J.; Arlandis, R.; Panizo, N.; Pascual, M.J.; Perez-Alba, A. Candida auris invasive infection after kidney transplantation. Case Rep. Nephrol. 2022, 2022, 6007607.
38. Apsemidou, A.; Füller, M.A.; Idelevich, E.A.; Kurzai, O.; Tragiannidis, A.; Groll, A.H. Candida lusitaniae breakthrough fungemia in an immuno-compromised adolescent: Case report and review of the literature. J. Fungi 2020, 6, 380.
39. Mnichowska-Polanowska, M.; Adamowicz, M.; Wojciechowska-Koszko, I.; Kisiel, A.; Wojciuk, B.; Jarosz, K.; Dolegowska, B. Molecular investigation of the fatal bloodstream Candida orthopsilosis infection case following gastrectomy. Int. J. Mol. Sci. 2023, 24, 6541.
40. Tsai, Y.T.; Lu, P.L.; Tang, H.J.; Huang, C.H.; Hung, W.C.; Tseng, Y.T.; Lee, K.-M.; Lin, S.-Y. The first invasive Candida auris infection in Taiwan. Emer. Microbes Infect. 2022, 11, 1867–1875.
41. Ohashi, Y.; Matono, T.; Suzuki, S.; Yoshino, S.; Alshahni, M.M.; Komori, A.; Makimura, K. The first case of clade I Candida auris candidemia in a patient with COVID-19 in Japan. J. Infect. Chemother. 2023, 29, 713–717.
42. Murata, S.; Mimura, K.; Kawamura, T.; Saito, H.; Ohno, H.; Tsujii, E.; Shinohara, T.; Miyazaki, Y.; Ohki, T. Bloodstream infection caused by Wickerhamiella pararugosa in a patient with intestinal obstruction: A case report. J. Infect. Chemother Off. J. Jpn. Soc. Chemother. 2024, 30, 942–945.
43. Xu, Z.; Zhang, L.; Han, R.; Ding, C.; Shou, H.; Duan, X.; Zhang, S. A candidemia case caused by a novel drug-resistant Candida auris with the Y132F mutation in Erg11 in Mainland China. Infect. Drug Resist. 2023, 16, 3065–3072.
44. Aboutalebian, S.; Nikmanesh, B.; Mohammadpour, M.; Charsizadeh, A.; Mirhend, H. Candida palmioleophila candidemia and bacterial co-infection in a 3-month-old infant with biliary atresia. Front. Cell Infect. Microbiol. 2023, 13, 1277607.
45. Awada, B.; Alam, W.; Chalfoun, M.; Araj, G.; Bizri, A.R. COVID-19 and Candida duobushaemulonii superinfection: A case report. J. Mycol. Med. 2021, 31, 101168.
46. Alashqar, M.B.; Alabdan, L.; Khan, M.; Almakadma, A.H.; Almustanyir, S. A case report of a Candida auris infection in Saudi Arabia. Cureus 2021, 13, e15240.
47. Mirhendi, H.; Charsizadeh, A.; Aboutalebian, S.; Mohammadpour, M.; Nikmanesh, B.; de Groot, T.; Meis, J.F.; Badali, H. South Asian (Clade I) Candida auris meningitis in a paediatric patient in Iran with a review of the literature. Mycoses 2022, 65, 134–139.
48. Mallick, D.C.; Kaushik, N.; Goyal, L.; Mallick, L.; Singh, P. A Comprehensive Review of Candidemia and Invasive Candidiasis in Adults: Focus on the Emerging Multidrug-Resistant Fungus Candida auris. Diseases 2025, 13, 93. [
49. Li, Y.; Gu, C.; Yang, Y.; Ding, Y.; Ye, C.; Tang, M.; Liu, J.; Zeng, Z. Epidemiology, antifungal susceptibility, risk factors, and mortality of persistent candidemia in adult patients in China: A 6-year multicenter retrospective study. BMC Infect. Dis. 2023, 23, 369.
50. Zeng, Z.; Ding, Y.; Tian, G.; Yang, K.; Deng, J.; Li, G.; Liu, J. A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China. Antimicrob. Resist. Infect. Control 2020, 9, 133.
51. Zeeshan, M.; Memon, S.; Malick, A.; Naqvi, S.F.; Farooqi, J.; Ghanchi, N.K.; Jabeen, K. Fluconazole-resistant Candida parapsilosis complex candidemia and analysis of mutations in the ERG11 gene from Pakistan. Mycoses 2024, 67, e13677.
52. Salmanton-García, J.; Cornely, O.A.; Stemler, J.; Barać, A.; Steinmann, J.; Siváková, A.; Akalin, E.H.; Arikan-Akdagli, S.; Loughlin, L.; Toscano, C.; et al. Attributable mortality of candidemia—Results from the ECMM Candida III multinational European Observational Cohort Study. J. Infect. 2024, 89, 106229.
53. Khan, Z.; Ahmad, S.; Al-Sweih, N.; Mokaddas, E.; Al-Banwan, K.; Alfouzan, W.; Al-Obaid, I.; Al-Obaid, K.; Asadzadeh, M.; Jeragh, A.; et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS ONE 2019, 14, e0216250.
54. Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin. Microbiol. Infect. 2014, 20 (Suppl. 6), 5–10.
55. Lamba, M.; Sharma, D.; Sharma, R.; Vyas, A.; Mamoria, V. To study the profile of Candida isolates and antifungal susceptibility pattern of neonatal sepsis in a tertiary care hospital of North India. J. Matern. Fetal Neonatal Med. 2021, 34, 2655–2659.
56. Subba, S.H.; Sharma, T.D.; Dopthapa, Y.P.; Bhutia, U.G.N.; Sharma, R. Candida glabrata meningitis in a patient with newly diagnosed acquired immunodeficiency syndrome from Sikkim, India. Curr. Med. Mycol. 2024, 10, e2024.345242.1542.
57. Najafzadeh, M.J.; Shaban, T.; Zarrinfar, H.; Sedaghat, A.; Hosseinikargar, N.; Berenji, F.; Jalali, M.; Lackner, M.; James, J.E.; Iikit, M. COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Med. Mycol. 2024, 62, myae031.
58. Arastehfar, A.; Hilmioğlu-Polat, S.; Daneshnia, F.; Hafez, A.; Salehi, M.; Polat, F.; Yasar, M.; Arslan, N.; Hosbul, T.; Unal, N.; et al. Recent increase in the prevalence of fluconazole-non-susceptible Candida tropicalis blood isolates in Turkey: Clinical implication of azole-non-susceptible and fluconazole tolerant phenotypes and genotyping. Front. Microbiol. 2020, 11, 587278.
59. Ponta, G.; Morena, V.; Strano, M.; Molteni, C.; Pontiggia, S.; Cavalli, E.M.; Grancini, A.; Mauri, C.; Castagna, A.; Galanti, A.; et al. Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: Two cases from Lecco Hospital (Italy). Antimicrob. Agents Chemother. 2024, 68, e0075024.
60. Trovato, L.; Bongiorno, D.; Calvo, M.; Migliorisi, G.; Boraccino, A.; Musso, N.; Oliveri, S.; Stefani, S.; Scalia, G. Resistance to echinocandins complicates a case of Candida albicans bloodstream infection: A case report. J. Fungi 2021, 7, 405.
61. Teixeira da Silva, F.; Cardoso, F.S.; Esteves, A.; Carvalho, J.; Maia, R. Relapsing Candida parapsilosis endocarditis with septic embolization: A case report. Cureus 2021, 13, e13159.
62. Arastehfar, A.; Daneshnia, F.; Hafez, A.; Khodavaisy, S.; Najafzadeh, M.J.; Charsizadeh, A.; Zarrinfar, H.; Salehi, M.; Shahrabadi, Z.Z.; Sasani, E. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med. Mycol. 2020, 58, 766–773.
63. Alghamdi, A.; Oravec, T.; Nishi, C.; Eckbo, E.; Marcon, K.; Wright, A.; Mah, A.; White, J.; Nevill, T.; Belga, S. Severe hypercalcemia as a result of disseminated Candida krusei infection. Int. J. Infect. Dis. 2024, 140, 110–112.
64. Prabhudas-Strycker, K.K.; Butt, S.; Reddy, M.T. Candida tropicalis endocarditis successfully treated with AngioVac and micafungin followed by long-term isavuconazole suppression. IDCases 2020, 21, e00889.
65. Paucar-Miranda, C.J.; Sandoval-Ahumada, R.E.; López-Martínez, R.L.; Terrel-Gutierrez, L.; Zurita-Macalapu, S.; Urcia-Ausejo, F.; Flores-León, D.; Gavilan-Chávez, R.; Quispe-Pardo, Z.; Yagui-Moscoso, M. Primer reporte de Candida auris en Perú. An. Fac. Med. 2021, 82, 56–61.
66. Li, Y.; Hind, C.; Furner-Pardoe, J.; Sutton, J.M.; Rahman, K.M. Understanding the mechanisms of resistance to azole antifungals in Candida species. JAC-Antimicrob. Resist. 2025, 7, dlaf106.
67. Pristov, K.E.; Ghannoum, M.A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 2019, 25, 792–798.
68. Carolus, H.; Pierson, S.; Lagrou, K.; Van Dijck, P. Anfotericin B and other polyenes: Discovery, clinical use, mode of action and drug rsistence. J. Fungi 2020, 6, 321.
69. Berman, J.; Krysan, D.J. Drug resistance and tolerance in fungi. Nat. Rev. Microbiol. 2020, 18, 539.
70. Czajka, K.M.; Venkataraman, K.; Brabant-Kirwan, D.; Santi, S.A.; Verschoor, C.; Appanna, V.D.; Singh, R.; Saunders, D.P.; Tharmalingam, S. Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species. Cells 2023, 12, 2655.
71. Wurster, S.; Albert, N.D.; Kontoyiannis, D.P. Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model. mSphere 2022, 7, e00817–e00821.
72. Pathakumari, B.; Liu, W.; Wang, Q.; Kong, X.; Liang, G.; Chokkakula, S.; Pathakamuri, V.; Nunna, V. Comparative Evaluation of Candida Species-Specific T-Cell Immune Response in Human Peripheral Blood Mononuclear Cells. Biomedicines 2024, 12, 1487.
73. Carey, B.; Lambourne, J.; Porter, S.; Hodgson, T. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1. Oral Dis. 2019, 25, 684–692.
74. Okada, S.; Markle, J.G.; Deenick, E.K.; Mele, F.; Averbuch, D.; Lagos, M. Impairment of immunity to Candida and Mycobacterium in humans with bi allelic RORC mutations. Science 2015, 349, 606–613.
75. Smeekens, S.P.; Plantinga, T.S.; van de Veerdonk, F.L.; Heinhuis, B.; Hoischen, A.; Joosten, L.A. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS ONE 2011, 6, e29248.
76. Zaongo, S.D.; Jing, O.; Stéphane, I.; Xin, Z.; Vijay, H.; Hongjuan, C.; Routy, J.-P.; Chen, Y. Candida albicans can foster gut dysbiosis and systemic inflammation during HIV infection. Gut Microbes 2023, 15, 2167171.
77. Savage, H.P.; Bays, D.J.; Tiffany, C.R.; Gonzalez, M.A.F.; Bejarano, E.J.; Carvalho, T.P.; Luo, Z.; Masson, H.L.P.; Nguyen, H.; Santos, R.L.; et al. Epithelial hypoxia maintains colonization resistance against Candida albicans. Cell Host Microbe 2024, 32, 1103–1113.e1106.
78. Guinan, J.; Wang, S.; Hazbun, T.R.; Yadav, H.; Thangamani, S. Antibiotic-induced decreases in the levels of microbial-derived short-chain fatty acids correlate with increased gastrointestinal colonization of Candida albicans. Sci. Rep. 2019, 9, 8872.
79. Huang, D.; Li, H.; Lin, Y.; Lin, J.; Li, C.; Kuang, Y.; Zhou, W.; Huang, B.; Wang, P. Antibiotic-induced depletion of Clostridium species increases the risk of secondary fungal infections in preterm infants. Front. Cell. Infect. Microbiol. 2022, 12, 981823.
80. Bromuro, C.; Posteraro, B.; Murri, R.; Fantoni, M.; Tumbarello, M.; Sanguinetti, M.; Dattilo, R.; Cauda, R.; Cassone, A.; Torosantucci, A. Identification of two anti Candida antibodies associated with the survival of patients with candidemia. mBio 2024, 15, e02769-23.
81. Sari, N.; Yanik Yalçin, T.; Erol, Ç.; Kurt Azap, Ö.; Arslan, H.; Karakaya, E.; Sezgin, A.; Haberal, M. Evaluation of Candidemia in Solid-Organ Transplant Recipients. Exp. Clin. Transplant. 2024, 22, 160–166.
82. Marinelli, T.; Pennington, K.M.; Hamandi, B.; Donahoe, L.; Rotstein, C.; Martinu, T.; Husain, S. Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis. Transpl. Infect. Dis. 2022, 24, e13812.
83. Puel, A. Human inborn errors of immunity underlying superficial or invasive candidiasis. Hum. Genet. 2020, 139, 1011–1022.
84. Silvester, E.J.; Watanabe, M.M.Y.; Pittet, L.F.; Boast, A.; Bryant, P.A.; Haeusler, G.M.; Daley, A.J.; Curtis, N.; Gwee, A. Candidemia in Children: A 16-year Longitudinal Epidemiologic Study. Pediatr. Infect. Dis. J. 2021, 40, 537–543.
85. Keighley, C.L.; Pope, A.; Marriott, D.J.E.; Chapman, B.; Bak, N.; Daveson, K. Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses 2021, 64, 257–263.
86. Rodrigues, C.F.; Rodrigues, M.E.; Henriques, M. Candida sp. Infections in Patients with Diabetes Mellitus. J. Clin. Med. 2019, 8, 76
87. Quiros-Roldan, E.; Sottini, A.; Natali, P.G.; Imberti, L. The Impact of Immune System Aging on Infectious Diseases. Microorganisms 2024, 12, 775.
88. Hesstvedt, L.; Gaustad, P.; Müller, F.; Torp Andersen, C.; Brunborg, C.; Mylvaganam, H.; leiva, R.A.; Berdal, J.E.; Ranheim, T.E.; Johnsen, B.O.; et al. The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infect. Dis. 2019, 51, 425–434.
89. Nascimento, T.; Inácio, J.; Guerreiro, D.; Patrício, P.; Proença, L.; Toscano, C.; Diaz, P.; Barroso, H. Insights into Candida Colonization in Intensive Care Unit Patients: A Prospective Multicenter Study. J. Fungi 2024, 10, 378.
90. Bassetti, M.; Vena, A.; Giacobbe, D.R.; Trucchi, C.; Ansaldi, F.; Antonelli, M.; Adamkova, V.; Alicino, C.; Almyroudi, M.-P.; Atchade, E.; et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infect. Dis. Ther. 2022, 11, 827–840.
91. Thomas-Rüddel, D.O.; Schlattmann, P.; Pletz, M.; Kurzai, O.; Bloos, F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022, 161, 345–355.
92. Dougherty, J.; Turner, N.A.; Yarrington, M.E.; Shaefer Spires, S.; Rebekah, W.M.; Alexander, B.D.; Park, L.P.; Johnson, M.D. Cumulative Antibiotic Exposure and Risk for Candidemia. Open Forum Infect. Dis. 2022, 9, ofac492.099.
93. Jung, P.; Mischo, C.E.; Gunaratnam, G.; Spengler, C.; Becker, S.L.; Hube, B.; Jacobs, K.; Bischoff, M. Candida albicans adhesion to central venous catheters: Impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. Virulence 2020, 11, 1453–1465.
94. Huang, L.; Li, S.; Jiang, R.; Lei, S.; Wu, J.; Huang, L.; Zhu, M. Glucocorticoid use and parenteral nutrition are risk factors for catheter-related Candida bloodstream infection: A retrospective study. Asian Biomed. (Res. Rev. News) 2024, 18, 109–115.
95. Malinovská, Z.; Čonková, E.; Váczi, P. Biofilm Formation in Medically Important Candida Species. J. Fungi 2023, 9, 955.
96. Gulati, M.; Nobile, C.J. Candida albicans biofilms: Development, regulation, and molecular mechanisms. Microbes Infect. 2016, 18, 310–321.
97. Oliva, A.; Venditti, M. Candidiasis invasiva en cirugía. In Infecciones en Cirugía. Actualizaciones en Cirugía; Bartoli, S., Cortese, F., Sartelli, M., Sganga, G., Eds.; Springer: Cham, Switzerland, 2025.
98. Meng, Y.; Kang, M.; Li, D.; Wang, T.; Kuang, Z.; Ma, Y. Performance of a new Candida anti-mannan IgM and IgG assays in the diagnosis of candidemia. Rev. Inst. Med. Trop. Sao Paulo 2020, 62, e25.
99. Barantsevich, N.; Barantsevich, E. Diagnosis and Treatment of Invasive Candidiasis. Antibiotics 2022, 11, 718.
100. Montagna, M.T.; Coretti, C.; Rella, A.; Barbuti, G.; Manca, F.; Montagna, O.; Laforgia, N.; Caggiano, G. The role of procalcitonin in neonatal intensive care unit patients with candidemia. Folia Microbiol. 2013, 58, 27–31.
101. Cortegiani, A.; Misseri, G.; Ippolito, M.; Bassetti, M.; Giarratano, A.; Martin-Loeches, I.; Einav, S. Procalcitonin levels in candidemia versus bacteremia: A systematic review. Crit. Care 2019, 23, 190.
102. Chen, B.; Li, W.; Pang, Y.; Zhang, N.; Bian, S.; Liu, C.; Yang, Z.; Jiang, Y.; Li, R.; Xie, Y.; et al. Rapid detection of fungi from blood samples of patients with candidemia using modified calcofluor white stain. J. Microbiol. Methods 2021, 184, 106202.
103. Kaur, H.; Kanaujia, R.; Singh, S.; Kajal, K.; Jayashree, M.; Peter, N.J.; Verma, S.; Gupta, M.; Ray, P.; Ghosh, A.; et al. Clinical utility of time to positivity of blood cultures in cases of fungaemia: A prospective study. Indian. J. Med. Microbiol. 2023, 43, 85–89
104. Keighley, C.; Pope, A.L.; Marriott, D.; Chen, S.C.; Slavin, M.A.; Australia and New Zealand Mycoses Interest Group. Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality. Med. Mycol. 2023, 61, myad028.
105. Bonfim-Mendonça, P.d.S.; Fiorini, A.; Shinobu-Mesquita, C.S.; Baeza, L.C.; Fernandez, M.A.; Svidzinski, T.I. Molecular typing of Candida albicans isolates from hospitalized patients. Rev. Inst. Med. Trop. 2013, 55, 385–391.
106. Camp, I.; Spettel, K.; Willinger, B. Molecular Methods for the Diagnosis of Invasive Candidiasis. J. Fungi 2020, 6, 101.
107. Mesini, A.; Mikulska, M.; Giacobbe, D.R.; Del Puente, F.; Gandolfo, N.; Codda, G.; Orsi, A.; Tassinari, F.; Beltramini, S.; Marchese, A.; et al. Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. Mycoses 2020, 63, 361–368.
108. Daneshnia, F.; Hilmioğlu-Polat, S.; Ilkit, M.; Fuentes, D.; Lombardi, L.; Binder, U.; Scheler, J.; Hagen, F.; Mansour, M.K.; Butler, G.; et al. Whole-genome sequencing confirms a persistent candidaemia clonal outbreak due to multidrug-resistant Candida parapsilosis. J. Antimicrob. Chemother. 2023, 78, 1488–1494.
109. Monday, L.M.; Parraga Acosta, T.; Alangaden, G. T2Candida for the Diagnosis and Management of Invasive Candida Infections. J. Fungi 2021, 7, 178.
110. Park, K.; Huh, J.W.; Choi, S.H.; Sung, H.; Kim, M.N. Clinical evaluation of the T2Candida assay for the rapid diagnosis of candidemia. Diagn. Microbiol. Infect. Dis. 2024, 110, 116406.
111. Krifors, A.; Ullberg, M.; Castegren, M.; Petersson, J.; Sparrelid, E.; Hammarström, H.; Sjolin, J.; Ozenci, V.; Blennow, O. T2Candida Assay in the Diagnosis of Intraabdominal Candidiasis: A Prospective Multicenter Study. J. Fungi 2022, 8, 86.
112. Camp, I.; Füszl, A.; Selitsch, B.; Kröckel, I.; Kovac, K.; Wahrmann, M.; Steinlechner, B.; Weber, J.; Schellongowski, P.; Zauner, C.; et al. Is the T2MR Candida Panel a suitable alternative to the SeptiFast for the rapid diagnosis of candidemia in routine clinical practice? Clin. Microbiol. Infect. 2024, 30, 816–821.
113. Park, B.; Oh, E.H.; Won, E.J.; Kang, J.; Jin, D.; Yoo, C.; Park, J.; Sung, H.; Kim, M.-N. Detection of clinically relevant Candida species from positive blood cultures using a novel sample-to-answer molecular assay. Sci. Rep. 2025, 15, 5417.
114. Balaji, L.; Manoharan, H.; Prabhakaran, N.; Manivannan, N. Time-to-Positivity for Candida in Bloodstream Infections: Prognostic Implications for Mortality. Cureus 2024, 16, e66364.
115. Aziz, H.S.A.; Ismail, D.K.; Mohammed, N.S.A.; Elgendy, M.O.; Bassiouny, D.M. Distribution and antifungal susceptibility profiles of Candida species isolated from candidemia patients admitted to Egyptian tertiary hospitals: A cross-sectional study. BMC Infect. Dis. 2024, 24, 1177.
116. de Souza, Â.C.; Pereira, D.C.; Barth, P.O.; Roesch, E.W.; Lutz, L.; Aquino, V.R.; Goldani, L.Z. Rapid identification, fluconazole and micafungin susceptibility testing of Candida species from blood culture by a short incubation method. Diagn. Microbiol. Infect. Dis. 2024, 109, 116271.
117. Meawed, T.E.; AlNakeera, A.M.; Attia, O.; Hassan, N.A.M.; Anis, R.H. Candida auris central line-associated blood stream infection in critically ill patients: The worst end of a bad scenario. Int. Microbiol. 2025, 28, 377–383.
118. Peter Donnelly, J.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376.
119. Dobiáš, R.; Káňová, M.; Petejová, N.; Pisti, Š.K.; Bocek, R.; Krejčí, E.; Struzkoca, H.; Cachová, M.; Tomasková, H.; Hamal, P.; et al. Combined Use of Presepsin and (1, 3)-β-D-glucan as Biomarkers for Diagnosing Candida Sepsis and Monitoring the Effectiveness of Treatment in Critically Ill Patients. J. Fungi 2022, 8, 308.
120. Zacharioudakis, I.M.; Zervou, F.N.; Marsh, K.; Siegfried, J.; Yang, J.; Decano, A.; Dubrovskaya, Y.; Mazo, D.; Aguero-Rosenfeld, M. Utility of incorporation of beta-D-glucan and T2Candida testing for diagnosis and treatment of candidemia. Diagn. Microbiol. Infect. Dis. 2024, 108, 116107.
121. Kinet-Poleur, A.; Deckers, C.; Saad Albichr, I.; Bogaerts, P.; Honoré, P.M.; Bulpa, P.; Ausselet, N.; Foret, F.; Kidd, F.; Huang, T.-D.; et al. Evaluation of Serum Biomarkers for Improved Diagnosis of Candidemia. J. Fungi 2025, 11, 224.
122. Lorenzo-Villegas, D.L.; Gohil, N.V.; Lamo, P.; Gurajala, S.; Bagiu, I.C.; Vulcanescu, D.D.; Horhat, F.G.; Sorop, V.B.; Diaconu, M.; Sorop, M.I.; et al. Innovative Biosensing Approaches for Swift Identification of Candida Species, Intrusive Pathogenic Organisms. Life 2023, 13, 2099.
123. Martin-Loeches, I.; Antonelli, M.; Cuenca-Estrella, M.; Dimopoulos, G.; Einav, S.; De Waele, J.J.; Garnacho-Montero, J.; Kanj, S.S.; Machado, F.R.; Montravers, P.; et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019, 45, 789–805.
124. Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2015, 62, e1–e50.
125. Aydin, S.; Derin, O.; Sahin, M.; Dinleyici, R.; Yilmaz, M.; Ceylan, B.; Tosun, A.I.; Ozturk, R.; Mert, A. Epidemiology of Nosocomial Candidemia, Mortality, and Antifungal Resistance: 7-Year Experience in Turkey. Jpn. J. Infect. Dis. 2022, 75, 597–603.
126. Horn, D.L.; Neofytos, D.; Anaissie, E.J.; Fishman, J.A.; Steinbach, W.J.; Olyaei, A.J.; Marr, K.A.; Pfaller, M.A.; Chang, C.-H.; Webster, K.M. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009, 48, 1695–1703.
127. Fang, X.; Su, C.; Luo, Y.; Pan, K.; Lin, J.; Song, Y.; Huang, Y.; Hu, X.; Shen, Z. Risk factors associated with short-term mortality in patients with candidemia and the predictive value of serum cytokine level. Cytokine 2025, 185, 156803.
128. Liu, F.; Shao, X.; Dong, Z.; Tang, K.; Zhong, L.; Xu, W.; Chen, Z.; Zheng, C.; Zhang, K.; Cai, J.; et al. Clinical characteristics and prognostic risk factors of candidemia in non-neutropenic patients: A retrospective cohort study. Eur. J. Clin. Microbiol. Infect. Dis. 2023, 42, 1389–1394.
129. Suh, J.W.; Kim, M.J.; Kim, J.H. Risk factors of septic shock development and thirty-day mortality with a predictive model in adult candidemia patients in intensive care units. Infect. Dis. 2021, 53, 908–919.
130. Kutlu, M.; Sayın-Kutlu, S.; Alp-Çavuş, S.; Öztürk, Ş.B.; Taşbakan, M.; Özhak, B.; Kaya, O.; Kutsoylu, O.E.; Senol-Akar, S.; Turhan, O.; et al. Mortality-associated factors of candidemia: A multi-center prospective cohort in Turkey. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 597–607.
131. Hoenigl, M.; Salmanton-García, J.; Egger, M.; Gangneux, J.P.; Bicanic, T.; Arikan-Akdagli, S.; Alastruey-Izquierdo, A.; Klimko, N.; Barac, A.; Ozenci, V.; et al. Guideline adherence and survival of patients with candidaemia in Europe: Results from the ECMM Candida III multinational European observational cohort study. Lancet Infect. Dis. 2023, 23, 751–761.
132. Sahoo, B.; Goyal, R.; Dutta, S.; Joshi, P.; Sanyal, K. Candida albicans: Insights into the Biology and Experimental Innovations of a Commonly Isolated Human Fungal Pathogen. ACS Infect. Dis. 2025, 11, 1780–1815.
133. Murphy, S.E.; Bicanic, T. Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. Front. Cell. Infect. Microbiol. 2021, 11, 759408.
134. Kollef, M.; Micek, S.; Hampton, N.; Doherty, J.A.; Kumar, A. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin. Infect. Dis. 2012, 54, 1739–1746.
135. Rouzé, A.; Loridant, S.; Poissy, J.; Dervaux, B.; Sendid, B.; Cornu, M.; Nseir, S.; Study Group S-TAFE. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: A randomized controlled trial. Intensive Care Med. 2017, 43, 1668–1677.
136. Paiva, J.A.; Charles, P.E. Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time? Intensive Care Med. 2017, 43, 1889–1891.
137. Healy, C.M.; Baker, C.J.; Zaccaria, E.; Campbell, J.R. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr. 2005, 147, 166–171.
138. Kaufman, D.; Boyle, R.; Hazen, K.C.; Patrie, J.T.; Robinson, M.; Grossman, L.B. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J. Pediatr. 2005, 147, 172–179.
139. Cokro, F.; Yolanda, L.; Caroline, S.; Studi Farmasi, P.; Kedokteran dan Ilmu Kesehatan, F. Fluconazole Effectiveness in Preventing Invasive Fungal Infection in Very Low Birth Weight Infants: Systematic Review and Meta-analysis (Efektivitas Flukonazol dalam Mencegah Infeksi Jamur Invasif pada Bayi dengan Berat Lahir Sangat Rendah: Tinjauan Sistematis dan Meta-analisis). J. Ilmu Kefarmasian Indonesia. 2022, 20, 14–22.
140. Lona-Reyes, J.C.; Gómez-Ruiz, L.M.; Cordero-Zamora, A.; Cortés-González, S.I.; Quiles-Corona, M.; Pérez-Ramírez, R.O.; Pinto-Macedo, H. Incidence and factors associated with invasive candidiasis in a neonatal intensive care unit in Mexico. An. Pediatr. (Engl. Ed.) 2022, 97, 79–86.
141. Estagnasié, C.; Mohr, C.; Kamus, L.; Zunic, P.; Chirpaz, E.; Moiton, M.P.; Lagrange-Xelot, M. Invasive fungal infections in patients with haematological malignancies at the University Hospital of Reunion Island (2018–2022): An observational study. Med. Mycol. 2024, 62, myae102.
142. Cornely, O.A.; Maertens, J.; Winston, D.J.; Perfect, J.; Ullmann, A.J.; Walsh, T.J.; Helfgott, D.; Holowiecki, J.; Stockelberg, D.; Goh, Y.-T.; et al. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. N. Engl. J. Med. 2007, 356, 348-59.
143. Boutin, C.A.; Durocher, F.; Beauchemin, S.; Ziegler, D.; Chakra, C.N.A.; Dufresne, S.F. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. Clin. Infect. Dis. 2024, 79, 151–160.
144. Rausch, C.R.; DiPippo, A.J.; Jiang, Y.; DiNardo, C.D.; Kadia, T.; Maiti, A.; Montalban-Bravo, G.; Ravandi, F. Kontoyiannis, D.P. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients with Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clin. Infect. Dis. 2022, 75, 1503–1510.
145. Calle-Miguel, L.; Garrido-Colino, C.; Santiago-García, B.; Moreno Santos, M.P.; Gonzalo Pascual, H.; Ponce Salas, B.; Beléndez Bieler, C.; Navarro Gómez, M.; Guinea Ortega, J.; Rincón-López, E.M. Changes in the epidemiology of invasive fungal disease in a Pediatric Hematology and Oncology Unit: The relevance of breakthrough infections. BMC Infect. Dis. 2023, 23, 348.
146. Cornely, O.A.; Sprute, R.; Bassetti, M.; Chen, S.C.A.; Groll, A.H.; Kurzai, O.; Lass-Florl, C.; Ostrosky-Zeichner, L.; Rautemaa-Richardson, R.; Revathia, G.; et al. Global guideline for the diagnosis and management of candidiasis: An initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect. Dis. 2025, 25, e280–e293.
147. Aslam, S.; Rotstein, C. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transpl. 2019, 33, e13623.
148. Carugati, M.; Arif, S.; Yarrington, M.E.; King, L.Y.; Harris, M.; Evans, K.; Barbas, A.S.; Sudan, D.L.; Perfect, J.R.; Miller, R.A.; et al. Limitations of antifungal prophylaxis in preventing invasive Candida surgical site infections after liver transplant surgery. Antimicrob. Agents Chemother. 2024, 68, e0127923.
149. López-Medrano, F.; de la Espada, M.M.; Asín, M.A.P.; Fernández-Ruiz, M.; Herrero-Martínez, J.M.; Alonso-Carrillo, J.; San Juan, R.; Rodríguez-Goncer, I.; Andrés, A.; González, E.; et al. Fluconazole versus micafungin for initial antifungal prophylaxis against Candida in pancreas transplant recipients: A comparative study of two consecutive periods. Mycoses 2022, 65, 517–525.
150. Bloos, F.; Held, J.; Kluge, S.; Simon, P.; Kogelmann, K.; de Heer, G.; Kuhn, S.-O.; Jarczak, D.; Motsch, J.; Hempel, G.; et al. (1 → 3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: The CandiSep randomized clinical trial. Intensive Care Med. 2022, 48, 865–875.
151. Erb, T.; Mihai, S.; Strauß, R.; Herbst, L.; Castellanos, I.; Diesch, K.; Cipa, F.; Bihlmaier, K.; Lang, A.-K.; Ganslmayer, M.; et al. β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: A randomized controlled study. Antimicrob. Agents Chemother. 2023, 67, e0072523.
152. Tissot, F.; Agrawal, S.; Pagano, L.; Petrikkos, G.; Groll, A.H.; Skiada, A.; Lass-Florl, C.; Calandra, T.; Viscoli, C.; Herbrecht, R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017, 102, 433–444.
153. Keighley, C.; Cooley, L.; Morris, A.J.; Ritchie, D.; Clark, J.E.; Boan, P.; Worth, L.J.; Australasian Antifungal Guidelines Steering Committee. Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Intern. Med. J. 2021, 51, 89–117.
154. Andes, D.R.; Safdar, N.; Baddley, J.W.; Playford, G.; Reboli, A.C.; Rex, J.H.; Sobel, J.D.; Pappas, P.G.; Kullberg, B.J.; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin. Infect. Dis. 2012, 54, 1110–1122.
155. Wolfgruber, S.; Sedik, S.; Klingspor, L.; Tortorano, A.; Gow, N.A.R.; Lagrou, K.; Gangneux, J.-P.; Maertens, J.; Meis, J.F.; Lass-Florl, C.; et al. Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV. Mycopathologia 2024, 189, 70.
156. Maseda, E.; Martín-Loeches, I.; Zaragoza, R.; Pemán, J.; Fortún, J.; Grau, S.; Aguilar, G.; Varela, M.; Borges, M.; Giménez, M.-J.; et al. Critical appraisal beyond clinical guidelines for intraabdominal candidiasis. Crit. Care 2023, 27, 382.
157. Pais, M.M.; Zaragoza, R.; Martín-Loeches, I.; Gómez-Bertomeu, F.F.; Rodríguez, A. Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review. J. Fungi 2025, 11, 362.
158. Kim, H.Y.; Baldelli, S.; Märtson, A.G.; Stocker, S.; Alffenaar, J.W.; Cattaneo, D.; Marriott, D.J. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther. Drug Monit. 2022, 44, 198–214.
159. Beyda, N.D.; John, J.; Kilic, A.; Alam, M.J.; Lasco, T.M.; Garey, K.W. FKS mutant Candida glabrata: Risk factors and outcomes in patients with candidemia. Clin. Infect. Dis. 2014, 59, 819–825.
160. Hoenigl, M.; Arastehfar, A.; Arendrup, M.C.; Brüggemann, R.; Carvalho, A.; Chiller, T.; Chen, S.; Egger, M.; Feys, S.; Ganneux, J.-P.; et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin. Microbiol. Rev. 2024, 37, e0007423.
161. Nagamizu, M.; Hotta, Y.; Noda, M.; Nakamura, D.; Hori, M.; Otsuka, Y.; Takemoto, R.; Horita, Y.; Wakita, E.; Morishita, N.; et al. Association of doses based on body constitutional parameters with the efficacy of micafungin in candidemia. J. Infect. Chemother. 2025, 31, 102654.
162. Alsowaida, Y.S.; Sulaiman, K.A.; Mahrous, A.J.; Alharbi, A.; Bifari, N.; Alshahrani, W.A.; Almangour, T.A.; Damfu, N.; Banamah, A.; Abu Raya, R.R.; et al. Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study. Int. J. Infect. Dis. 2024, 148, 107234.
163. Thompson, G.R.; Soriano, A.; Skoutelis, A.; Vazquez, J.A.; Honore, P.M.; Horcajada, J.P.; Spapen, H.; Bassetti, M.; Ostrosky-Zeichner, L.; Das, A.F.; et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin. Infect. Dis. 2021, 73, E3647–E3655.
164. Thompson, G.R.; Soriano, A.; Cornely, O.A.; Kullberg, B.J.; Kollef, M.; Vazquez, J.; Honore, P.M.; Bassetti, M.; Pullman, J.; Chayakulkeeree, M.; et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023, 401, 49–59.
165. Soriano, A.; Locke, J.B.; Cornely, O.A.; Roilides, E.; Ramos-Martinez, A.; Honoré, P.M.; Castanheira, M.; Carvalhaes, C.G.; Nseir, S.; Bassetti, M.; et al. Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: Pooled analyses of two randomized trials of rezafungin versus caspofungin. Clin. Microbiol. Infect. 2025, 31, 250–257.
166. Nucci, M.; Anaissie, E.; Betts, R.F.; Dupont, B.F.; Wu, C.; Buell, D.N.; Kovanda, L.; Lortholary, O. Early removal of central venous catheter in patients with candidemia does not improve outcome: Analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 2010, 51, 295–303.
167. Nucci, M.; Braga, P.R.; Nouér, S.A.; Anaissie, E. Time of catheter removal in candidemia and mortality. Braz. J. Infect. Dis. 2018, 22, 455–461.
168. Lee, Y.M.; Ryu, B.H.; Hong, S.I.; Cho, O.H.; Hong, K.W.; Bae, I.G.; Kwack, W.G.; Kim, Y.J.; Chung, E.K.; Kim, D.Y.; et al. Clinical impact of early reinsertion of a central venous catheter after catheter removal in patients with catheter-related bloodstream infections. Infect. Control. Hosp. Epidemiol. 2021, 42, 162–168.
169. Zuo, X.S.; Liu, Y.; Cai, X.; Zhan, L.; Hu, K. Association of different Candida species with catheter-related candidemia, and the potential antifungal treatments against their adhesion properties and biofilm-forming capabilities. J. Clin. Lab. Anal. 2021, 35, e23738.
170. Breazzano, M.P.; Bond, J.B.; Bearelly, S.; Kim, D.H.; Donahue, S.P.; Lum, F.; Olsen, T.W.; American Academy of Ophthalmology. American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis. Ophthalmology 2022, 129, 73–76.
171. Breazzano, M.P.; Day, H.R.; Bloch, K.C.; Tanaka, S.; Cherney, E.F.; Sternberg, P.; Donahue, S.P.; Bond 3rd, J.B. Utility of Ophthalmologic Screening for Patients with Candida Bloodstream Infections: A Systematic Review. JAMA Ophthalmol. 2019, 137, 698–710.
172. Phongkhun, K.; Pothikamjorn, T.; Srisurapanont, K.; Manothummetha, K.; Sanguankeo, A.; Thongkam, A.; Chuleerarux, N.; Leksuwankun, S.; Meejun, T.; Thanakitcharu, J.; et al. Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients with Candidemia: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2023, 76, 1738–1749.
173. Lehman, A.; Tessier, K.M.; Sattarova, V.; Montezuma, S.R.; Kline, S.; Erayil, S.E. Do Patients With Candidemia Need an Ophthalmologic Examination? Open Forum Infect. Dis. 2024, 11, ofae663.
174. Shin, S.U.; Yu, Y.H.; Kim, S.S.; Oh, T.H.; Kim, S.E.; Kim, U.J.; Kang, S.-J.; Jang, H.-C.; Park, K.-H.; Jung, S.I. Clinical characteristics and risk factors for complications of candidaemia in adults: Focus on endophthalmitis, endocarditis, and osteoarticular infections. Int. J. Infect. Dis. 2020, 93, 126–132.
175. Soriano, A.; Honore, P.M.; Puerta-Alcalde, P.; Garcia-Vidal, C.; Pagotto, A.; Gonçalves-Bradley, D.C.; Verweij, P.E. Invasive candidiasis: Current clinical challenges and unmet needs in adult populations. J. Antimicrob. Chemother. 2023, 78, 1569–1585.
176. Permpalung, N.; Sedik, S.; Pappas, P.G.; Hoenigl, M.; Ostrosky-Zeichner, L. Diagnosis and Management of Candida Endophthalmitis and Chorioretinitis. Clin. Microbiol. Infect. 2025; in press.
177. Turner, R.B.; Valcarlos, E.; Won, R.; Chang, E.; Schwartz, J. Impact of infectious diseases consultation on clinical outcomes of patients with Staphylococcus aureus bacteremia in a community health system. Antimicrob. Agents Chemother. 2016, 60, 5682–5687.
178. Kobayashi, T.; Marra, A.R.; Schweizer, M.L.; Eyck, P.T.; Wu, C.; Alzunitan, M.; Salinas, J.L.; Siegel, M.; Farmakiotis, D.; Auwaerter, P.G.; et al. Impact of infectious disease consultation in patients with candidemia: A retrospective study, systematic literature review, and meta-analysis. Open Forum Infect. Dis. 2020, 7, ofaa270.
179. Lee, R.A.; Vo, D.T.; Zurko, J.C.; Griffin, R.L.; Rodriguez, J.M.; Camins, B.C. Infectious diseases consultation is associated with decreased mortality in enterococcal bloodstream infections. Open Forum Infect. Dis. 2020, 7, ofaa064.
180. Schmitt, S.; McQuillen, D.P.; Nahass, R.; Martinelli, L.; Rubin, M.; Schwebke, K.; Petrak, R.; Ritter, J.T.; Chansolme, D.; Slama, T.; et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin. Infect. Dis. 2014, 58, 22–28.